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The main objective of the work presented was to determine if the 
cyclooxygenase (COX) enzymes are involved in ovarian carcinogenesis in the 
hen as a model for the human disease.  The expression patterns of COX-1 and 
-2 mRNA and protein in normal hen ovaries and hen ovarian tumors were 
determined.  COX-1 mRNA expression was significantly increased in ovarian 
tumors of the hen while there was no difference in COX-2 mRNA expression 
in normal hen ovaries as compared to ovarian tumors.  COX-1 protein 
localized to glandular areas of ovarian tumors and a significant increase in 
prostaglandin E2 (PGE2) in ovarian tumors indicated that the increase in COX-
1 mRNA represented a functional increase.  The expression of COX-1, COX-2, 
and vascular endothelial growth factor (VEGF) mRNA and protein were also 
determined in ascites cells collected from hens with ovarian cancer.  VEGF 
was previously associated with COX-1 expression in human ovarian cancer 
and is implicated in the etiology of ovarian cancer, including ascites 
formation.  We found a significant increase in VEGF mRNA in ascites cells 
collected from hens with ovarian cancer as compared to normal hen ovaries 
and a correlation between ascitic VEGF mRNA expression and ascites volume.  
VEGF protein was expressed in ascites cells and also localized to glandular 
areas of ovarian tumors.   We found no indication that treatment with COX 
 inhibitors decreased VEGF expression, but our data show that ascites cell 
proliferation could be decreased using a nonspecific (aspirin) or a COX-1 
specific inhibitor, while equivalent concentrations of a COX-2 specific 
inhibitor were ineffective at decreasing proliferation.  Finally, the effect of 
feeding hens a diet containing aspirin (a common COX inhibitor) on ovarian 
cancer incidence and/or progression was determined.  We found a significant 
effect of aspirin treatment on the stage of ovarian cancer, which indicates that 
inhibition of the COX enzymes may slow the progression of the disease.  
These combined data suggest that the COX enzymes, in particular COX-1, 
contribute to ovarian carcinogenesis in the hen, which supports data in 
women.  The hen, therefore, may be the ideal spontaneous in vivo model for 
studies involving the COX enzymes and ovarian cancer. 
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CHAPTER 1 
LITERATURE REVIEW 
Ovarian Cancer 
Ovarian cancer is the most fatal gynecologic malignancy in the western 
world [1].  The high mortality rate associated with ovarian cancer is due in 
part to vague symptoms associated with early disease, lack of effective 
screening techniques to detect early cases and inadequate treatment options 
for patients with advanced stages of the disease.  A lack of understanding of 
the underlying mechanisms behind the development and progression of 
ovarian adenocarcinoma is the main impediment to decreasing deaths due to 
ovarian malignancy. 
The International Federation of Gynecology and Obstetrics (FIGO) 
developed a widely used staging system for ovarian cancer, consisting of four 
stages that describe the advancement of ovarian tumor growth [2, 3].  Stage I 
describes growth limited to the ovaries.  Once growth spreads beyond the 
ovaries into pelvic organs, the cancer is considered Stage II.  Patients with 
growth of tumors that involves one or both ovaries with peritoneal metastasis 
beyond the pelvis are classified as Stage III.  Finally, Stage IV describes cancers 
that involve one or both ovaries with distant metastasis beyond the peritoneal 
cavity.  More than 70% of women are initially diagnosed with Stage III or IV 
ovarian cancer according to the FIGO classification [4]. 
The five-year survival rate of ovarian cancer patients ranges from 80-
90% for FIGO Stage I to 5-20% for FIGO Stage IV [3].  Because survival is 
strongly inversely correlated with stage, identification of women with early 
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stages of ovarian cancer is crucial for their survival.  Until recently, women 
with early stages of ovarian cancer were considered asymptomatic, which 
explains why the majority of early cases are not detected.  In 2007, the 
Gynecologic Cancer Foundation, Society of Gynecologic Oncologists, and 
American Cancer Society made a consensus statement regarding symptoms of 
ovarian cancer [5].  This statement defined the symptoms as including 
bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and 
urinary symptoms including urgency or frequency.  Studies have shown that 
even early stage ovarian cancer can produce these symptoms [5].  The 
symptoms of ovarian cancer remain relatively vague, however, and many 
patients may still delay seeking medical attention until the cancer has 
progressed to a later stage.   
Most ovarian tumors can be classified into one of three main categories, 
divided according to the cell type of origin for the malignancy: sex cord-
stromal, germ cell tumors, and surface epithelial-stromal tumors [6, 7].  Sex 
cord-stromal tumors develop from the transformation of theca, granulosa, or 
stromal cells, while germ cell tumors develop from primordial germ cells.  
Surface epithelial-stromal tumors, better known as epithelial ovarian cancers 
(EOCs), arise from the ovarian surface epithelium (OSE) and are believed to be 
the source of the majority (> 85%) of human ovarian cancers [7, 8].  
The OSE is contiguous with the peritoneal mesothelium [9] and EOCs 
are characteristically heterogenous in nature.  The underlying molecular and 
genetic events leading to ovarian adenocarcinoma are still largely unknown.  
OSE cells develop the characteristics of other mullerian duct-derived cells as 
malignant transformation occurs.  Epithelial tumors are therefore divided into 
five major subtypes based on the characteristics the tumor cells acquire: serous 
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(fallopian tube-like), mucinous (endocervical-like), endometrioid 
(endometrium-like), clear cell (resembles endometrial glands in pregnancy), 
and Brenner tumors (urothelial in appearance) [6, 7, reviewed in [10]]. There 
are also mixed forms, unclassified forms, and undifferentiated carcinomas [7].  
Nearly 80% of all EOCs are categorized as serous [8].  The subtypes of EOC 
differ not only in morphology but also with respect to occurrence, response to 
chemotherapy, and survival rates.  Generally speaking, survival rates for 
women with EOC decrease for cancers diagnosed at later stages, at older ages, 
with larger volume of tumor and for women diagnosed with clear cell or 
undifferentiated cancers [11-15].  There also appears to be a survival 
advantage of Hispanic and Filipina women and a survival disadvantage for 
African-American women as compared to white women [11].   
 Only 5-10% of ovarian cancers can be explained by genetic 
predisposition or family history and a number of hypotheses have been 
developed in an attempt to explain the origin of spontaneous ovarian cancer.  
Two leading hypotheses are the incessant ovulation hypothesis and the 
gonadotropin stimulation hypothesis.  The incessant ovulation hypothesis was 
first presented in 1971 by Fathalla [16].   In this hypothesis, it is proposed that 
the repeated rupture and repair of the OSE with each ovulation stimulates 
proliferation and permits transformation to occur.  Through repeated trauma 
of OSE cells, it is thought that mutations may be incorporated into the 
genome, possibly due to exposure of OSE cells to genotoxins that are 
generated during the ovulatory process [17].   Alternatively, cells of the OSE 
may be exposed to a novel environment following the incorporation of these 
cells into the ovarian stroma in the form of inclusion cysts [8].  Inclusion cysts 
are believed to arise through one of two possible mechanisms (Fig. 1-1).  OSE  
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Adapted from Auersperg et al. [8]. 
Inclusion cysts can form through the incorporation of fragments of the OSE 
into ruptured follicles or through the pinching off of surface clefts [8].  
 
 
 
Figure 1-1.  The formation of inclusion cysts. 
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cells may be displaced following ovulation if they become trapped within 
ruptured follicles.  Alternately, OSE cells lining natural clefts on the ovarian 
surface may be pinched off and incorporated into the stroma of the ovary [8].  
The incessant ovulation hypothesis has been supported by the fact that 
ovarian cancer risk is increased by nulliparity, while a history of one or more 
full term pregnancies and use of oral contraceptives decreases a woman’s risk 
[18, 19].  Weaknesses in this theory exist, however.  For example, 
progesterone-only contraceptives, which do not completely inhibit ovulation, 
also decrease a woman’s risk of EOC as effectively as ovulation-inhibiting 
contraceptives, and women with polycystic ovarian syndrome (PCOS), who 
have decreased ovulatory cycles, are at increased risk of the disease [reviewed 
in [20]].  
 The gonadotropin stimulation hypothesis was developed after the 
incessant ovulation hypothesis, and proposes that over-stimulation by 
gonadotropins, specifically follicle stimulating hormone (FSH) and luteinizing 
hormone (LH) leads to malignant transformation of the OSE.  This hypothesis 
was developed after the observation that rodents that underwent bilateral 
oophorectomy with transplantation of the ovary under the splenic capsule 
developed ovarian tumors, while intact ovarian function in these animals 
suppressed tumor formation [reviewed in [21]].  Loss of ovarian function 
leads to decreased negative feedback to the hypothalamic-pituitary axis and a 
subsequent increase in gonadotropin release.  Indirect evidence for this 
hypothesis includes the fact that gonadotropin levels are known to increase 
with age, being particularly high in early menopause, which  may explain the 
increased incidence of ovarian cancer in post-menopausal women.  
Additionally, infertile women who use fertility drugs have been reported to 
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have an increased risk of EOC [20].  Cramer and Welch [22] proposed that 
after inclusion cysts form, differentiation, proliferation, and malignant 
transformation occur as a result of either direct stimulation by gonadotropins 
or by indirect stimulation by steroids stimulated by gonadotropins.  They 
argued that the fact that pregnancy decreases the risk of ovarian cancer 
supports the gonadotropin stimulation hypothesis because pregnancy may 
cause permanent changes in the pituitary gland that affect the secretion of 
trophic hormones.  Similarly, they believe that the fact that oral contraceptive 
use lowers gonadotropin secretion and decreases a woman’s risk of ovarian 
cancer supports their theory [22].  A recent study using a genetically modified 
mouse model lacking ovulation with high gonadotropin levels found 
increased incidence of ovarian tumors, which provides additional support for 
the gonadotropin stimulation hypothesis [23].  
Other hypotheses that were developed to explain the development of 
ovarian cancer that may be considered not as widely accepted include the 
inflammation hypothesis, the hormonal stimulation hypothesis, and the pelvic 
contamination theory.  The inflammation hypothesis suggests that 
lymphocytes, growth factors, and prostaglandins associated with 
inflammation may contribute to cancer growth and to immunosuppression 
associated with cancer advancement [24, 25].  The inflammation-induced 
transcription factor, nuclear factor κB, is believed to play a key role in cancer 
through the inhibition of apoptosis [26].  With respect to ovarian cancer, 
inflammation is induced in damaged OSE with each ovulation and aspects of 
the ovulatory process have been described as resembling an acute 
inflammatory process [27].  Evidence supporting this theory includes the fact 
that use of non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the 
 7 
risk of ovarian cancer [28-31], exposure to inflammation-inducing agents such 
as talc or asbestos increases risk [reviewed in [20]], and conditions such as 
endometriosis or pelvic inflammatory disease are associated with ovarian 
cancer development [25].   
Theories involving the effect of hormones on ovarian cancer risk 
suggest that androgens and possibly estrogens promote carcinogenesis, while 
progestins may have protective effects.  Evidence in support of the hormonal 
stimulation hypothesis include the fact that levels of androgens in growing 
follicles <10mm in diameter are more than 10 times greater than that of 
estradiol, which may mean that epithelial cells within inclusion cysts would 
be exposed to high androgen levels [reviewed in [21]].  The presence of 
androgen receptors on human OSE cells and the ability of these cells to 
increase proliferation and decrease apoptosis with androgen stimulation have 
been shown [32].  Additionally, an analysis of the expression of hormone 
receptors in 94 samples of untreated ovarian tumor samples showed that 
androgen receptors were present in 90% of samples, while estrogen and 
progesterone receptors were present in 55% and 52%, respectively [33].  
Furthermore, PCOS is associated with increased androgens and increased risk 
of ovarian cancer, and oral contraceptive use decreases ovarian testosterone 
production [reviewed in [21]].  Progesterone, on the other hand, decreases risk 
of EOC [reviewed in [20]] and induces apoptosis in human ovarian cancer cell 
lines [34].  It has also been suggested that estrogens may play a role in ovarian 
cancer development.  Studies have indicated an increase in the ratio of the two 
estrogen receptor (ER) subtypes, ERα to ERβ, in ovarian tumors and cells 
isolated from ovarian tumors [35, 36].  It is hypothesized that ERβ may 
stimulate anti-proliferative effects that protect against ERα- induced 
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hyperproliferation [37], which may explain why ERβ is down-regulated in 
neoplastic ovarian tissue [38, 39].  In addition, epidemiological data suggest 
that long-term use of hormone replacement therapy increases risk of EOC 
[reviewed in [40]].  Indirect evidence that supports a role for estrogens in 
ovarian carcinogenesis includes the fact that breast-feeding and oral 
contraceptive use, which both decrease risk of EOC also decrease estradiol 
production [reviewed in [21]].  Pregnancy, however, increases serum estradiol 
as much as 100-fold and has a protective effect [reviewed in [21]].   
The pelvic contamination theory suggests that ovarian cancer is 
initiated after carcinogens ascend the reproductive tract and act at the ovary, 
while others believe that systemic carcinogens such as tobacco smoke may be 
the impetus behind ovarian cancer initiation [reviewed in [22]].  It remains to 
be seen whether one of these theories or perhaps a combination of two or 
more of these theories accurately define the cause of ovarian cancer.  Until one 
is proven doctrine, all theories should be considered sources of intriguing 
opportunities for research potential.      
Several prognostic factors are used to determine the relevant treatment 
for ovarian carcinoma patients including surgical stage, volume of residual 
tumor after primary surgery and histological grade [4].  Surgery is most 
commonly the first treatment followed by chemotherapy, although the reverse 
of this order is used in some cases.  A combination of paclitaxel and 
carboplatin or carboplatin alone is the standard first-line chemotherapy for 
advanced ovarian cancer [41].  Paclitaxel is a mitotic inhibitor that binds the β-
subunit of tubulin, which prevents microtubule breakdown [42].  As described 
in a recent review [43], microtubule stabilization can lead to the induction of 
apoptosis through a p53-dependent pathway or through the MAPK pathway, 
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which activates pro-apoptotic proteins such as BAD.  Additionally, the fact 
that the pro-apoptotic protein, BIM, is bound to a microtubule-bound ATPase 
indicates that paclitaxel-induced microtubule stabilization could directly 
activate an apoptotic pathway [43].  Carboplatin is a DNA alkylating agent 
that induces the formation of platinum-DNA adducts, crosslinks, and strand 
breaks which inhibit DNA replication [42].  The interstrand and intrastrand 
crosslinks formed by platinum-DNA adducts also activate the mismatch 
repair pathway, which triggers apoptosis [reviewed in [43]].  The standard 
second line for ovarian cancer treatment depends on a number of factors 
including the type of initial treatment, time elapsed before recurrence, 
tolerability, the patient’s performance status, and cost-effectiveness [41].   
Because the aim of tumor-debulking surgery is to remove as much of 
the tumor as possible and most ovarian carcinomas are not diagnosed until 
the cancer has spread beyond the ovaries, considerable morbidity is associated 
with surgery as treatment for ovarian cancer [44].  Despite this, surgery 
appears to be necessary for ovarian cancer treatment because the recurrence of 
cancer for patients receiving only systemic chemotherapy is around 80% and 
recurrence is a predictor of poor outcome [41, 45].  Additionally, most patients 
with advanced EOC exhibit poor initial response to chemotherapy or develop 
resistance to chemotherapy [46, 47].  Chemoresistance in ovarian tumors can 
occur due to genetic or nongenetic alterations that allow the tumor to increase 
drug inactivation, enhance efflux of the drug, increase DNA damage repair, 
decrease apoptotic pathways, or increase survival signals [43].  In addition, 
quiescent cells within the tumor may be unaffected by chemotherapy because 
most chemotherapeutic drugs require the cell to be active in the cell cycle [42].  
There is evidence that resistance to chemotherapeutic agents varies among 
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histologic subtypes of EOC due to differences in tumor cell biology among the 
subtypes, reflected in differences in biomarker expression [10].  The poor 
efficacy of treatments of advanced ovarian cancer make studies aimed at 
enhancing prevention or early detection of the disease pertinent.  As a means 
to this end, many studies are focused on determining relevant pathways 
involved in the development or progression of ovarian cancer. 
 
The Cyclooxygenase Enzymes in Ovarian Cancer 
The COX enzymes are the key regulatory enzymes in the prostaglandin 
synthesis pathway (Fig. 1-1).  Abnormal production of prostaglandins due to 
aberrant expression of the COX enzymes has been associated with multiple 
malignancies, including ovarian cancer.  Prostaglandins are thought to 
contribute to carcinogenesis through the enhancement of cell growth, 
inhibition of apoptosis, and modulation of the immune system, and have also 
been associated with increased cell proliferation, enhanced tumor 
invasiveness, and metastatic potential [49-51].  Additionally, the production of 
stable oxy radicals and the formation of malondialdehyde are catalyzed by 
prostaglandins and both may lead to the formation of mutations that may 
eventually trigger tumor formation [49].  Few studies actually document 
changes in the levels of prostanoids in cancer and data regarding the 
expression of the COX enzymes and downstream isomerases are used to 
deduce the involvement of prostanoids in tumor progression [52]. 
The five major prostanoids produced from the COX reactions are 
prostaglandin F2α (PGF2α), prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), 
prostaglandin I2 (PGI2), and thromboxane A2 (TxA2) [52].  As explained by  
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Adapted from Dubois et al. [48].  
 
 
 
 
Figure 1-2.  Production of prostglandins from arachidonic 
acid.   
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Narumiya et al., prostaglandins are named according to modifications to their 
cyclopentane ring, while thromboxanes have an oxane ring in the place of the 
cyclopentane ring.  PGI and TxA are chemically unstable with a half-life of 30 
seconds to a few minutes before they are degraded into inactive products.  
Other prostaglandins are chemically stable but are metabolized quickly, in a 
single passage through the lung [reviewed in [53]].  Prostaglandins are 
therefore believed to act locally and participate in a wide range of biological 
functions including but not limited to platelet aggregation, immune function, 
kidney development, renal homeostasis, uterine function, pregnancy, 
parturition, sleep wake cycle, body temperature, and inflammation [reviewed 
in [52]].    
Two COX isoforms currently being studied with respect to cancer risk 
are COX-1 and COX-2.  COX-1 and COX-2 share around 60% sequence 
identity and are ~600 amino acids in chickens and mammals.  Additionally, 
both isoforms catalyze identical reactions in the conversion of arachidonic acid 
to prostaglandins.  COXs have bifunctional enzymatic activity that includes a 
cyclooxygenase reaction, that produces an endoperoxide-containing 
prostaglandin G2 (PGG2), and a peroxidase reaction, in which a hydroperoxyl 
in PGG2 is reduced to a hydroxyl to form PGH2 [Figure 1-2; reviewed in [54]].  
Specific synthases then transform PGH2 into different prostaglandins.  The 
peroxidase activity of the COX enzymes can function independent of the 
cyclooxygenase activity, but the reverse is not true [55].  Despite the 
similarities, COX-1 and COX-2 are located on different genes that are 
separately regulated and have distinct expression patterns.  
Habenicht et al. [56] noted that treatment of Swiss 3T3 cells (an  
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Adapted from Smith et al. [58]. 
Figure 1-3.  The formation of prostaglandin from 
arachidonic acid, catalyzed by the cyclooxygenase and 
peroxidase activities of the COX enzymes.  
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immortal line of fibroblast-like cells derived from whole trypsinized embryos 
of Swiss mice) with platelet-derived growth factor (PDGF), induced 
prostaglandin synthesis in two separate peaks: an early peak at 10 min and a 
late peak 2-4 hours after treatment.  This led to the conclusion that PDGF-
stimulated prostaglandin synthesis must occur through two direct effects on 
the COX system, one involving a protein-synthesis independent mechanism 
and another that requires rapid translation of COX [56].  In 1991 the combined 
work of three independent groups led to the identification of COX-2 
[reviewed in [54]].  The origin of multiple cyclooxygenase enzymes is believed 
to be the result of the duplication of the COX gene independently in 
invertebrates and vertebrates, although the reason for separate isozymes is 
unknown [57].  Despite the probable common origin, the two isoforms are 
differentially regulated in terms of mRNA splicing, stability, and translational 
efficiency [48].  In addition, COX-1 and COX-2 appear to be able to utilize 
different substrate pools.  For example, in both fibroblasts and immune cells, 
endogenous arachidonic acid is utilized by COX-2, while COX-1 requires 
exogenous substrate [48].  This suggests that the availability of endogenous or 
exogenous arachidonic acid is a regulatory element that may differentially 
control prostaglandin production by the two COX isoforms in certain cell 
types.  
COX-1 had long been known as the constitutively expressed COX 
isozyme and is involved in producing prostaglandins that perform 
“housekeeping” functions including smooth muscle contraction, the 
regulation of renal water and sodium metabolism, stomach acid secretion, 
platelet aggregation, renin release, and parturition [reviewed in [59], 60, 61].  
Recent data indicate that COX-1 may be inducible under certain conditions 
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[62] and, as will be discussed below, COX-1 may not only be involved in 
“housekeeping” functions.  COX-1 expression can be found in most 
mammalian tissues [48, 63].  COX-2 had been known as the inducible isoform 
associated with inflammatory states [64].  COX-2 expression is inducible in  
endothelial cells, macrophages, fibroblasts, and ovarian follicles by various 
stimuli including mitogens, cytokines, growth factors, and hormones 
[reviewed in [48], 65, 66, 67].  Despite the fact that COX-2 is considered 
inducible, it is now known to be constitutively expressed in some tissues 
including the brain and kidney of rodents and in human and rabbit gastric 
mucosa [68, 69, 70].   
The generation of COX knockout (KO) mice resulted in surprising 
phenotypes.  Because COX-1 was considered the isoform responsible for 
homeostasis, it was expected that COX-1 deficiency would be detrimental.  
Lagenbach et al. [71] used homologous recombination to disrupt COX-1 in the 
mouse and surprisingly found that the only abnormality observed was a 
decreased inflammatory response to arachidonic acid.  Neither male nor 
female fertility was affected, development was normal, and no significant 
pathology was observed in the liver, spleen, kidney, heart, lungs, GI or 
reproductive tracts.  Breedings between homozygous mutant females and 
heterozygous males (and vice versa) resulted in litter sizes and surviving pups 
close to normal.  Only breedings between homozygous mutant females and 
homozygous mutant males resulted in death of all resulting pups despite 
normal litter sizes.  The death of pups was hypothesized to be due to impaired 
onset of labor [71].   Results from COX-2 KO mice, reported by Dinchuk et al. 
[72], included renal dysplasia (100% penetrance) and cardiac fibrosis (50% 
penetrance).  Although COX-2 deficiency was not lethal in utero, neonatal 
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death was common and average lifespan of null animals was 3.5 months.  
COX-2 deficient females were largely infertile and had ovaries that were 
virtually void of corpora lutea but had apparently normal follicle 
development.  These data were interpreted as showing that inhibition of COX-
2 inhibits ovulation [72].  The results from COX-1 and COX-2 KO mice 
indicate that the functional roles of these two isozymes are not as defined or 
distinct as was once believed.  For example, if COX-1 is only responsible for 
homeostasis and if COX-2 is only responsible for inflammatory responses, 
then the lack of significant pathology and decreased inflammatory response 
seen in mice lacking COX-1 activity is contradictory.  Furthermore, the normal 
inflammatory response observed in COX-2 KO mice indicates that COX-1 
contributes to this process.   
In addition to the data gathered from COX KO mice, further evidence 
shows that the COX enzymes serve multiple functional roles.  As mentioned 
above, the inducible isoform, COX-2, now is known to be constitutively 
expressed in some tissues.  Most notably, constitutive expression of COX-2 in 
human gastric mucosa [70] adds to evidence that suggests that COX-2 may 
catalyze the production of prostaglandins with a protective function 
[reviewed in [73]].  Data show that gastric and intestinal damage in rats is only 
seen after both COX-1 and COX-2 are inhibited [74, 75] and specific inhibition 
of COX-2 results in decreased gastric ulcer healing in both mice and rats [76, 
77].  COX-2 is also involved in normal renal development and contributes to 
myocardial protection [63].  A study by Gilroy et al. in 1999 [78] showed that 
COX-2 activity is associated with anti-inflammatory actions, in addition to its 
known pro-inflammatory function.  In their rat model of inflammation, two 
peaks of COX-2 activity were observed: one at 2 hours and a second at 48 
 17 
hours.  The activity observed at the second peak was 350% greater than that at 
the first peak and coincided with a decrease in the inflammatory reaction.  
Inhibition of COX-2 using indomethacin or a specific COX-2 inhibitor 
decreased inflammation at 2 hours but resulted in increased inflammation at 
48 hours [78].  These combined data suggest that interactions and functions of 
COX-1 and COX-2 are more complex than was originally believed and further 
research is warranted to accurately determine effects of inhibiting these 
enzymes. 
In the last 2 decades, many studies have focused on the possibility that 
the COX enzymes may play a role in cancer formation or progression. COX-2 
expression has been associated with cancers of the colon, breast, head, neck, 
pancreas, lung, and stomach, among others [79-85].  Additionally, studies in 
transgenic mice have shown that overexpression of COX-2 is sufficient to 
induce mammary gland tumorigenesis, possibly by altering levels of anti- and 
pro-apoptotic proteins [86].  Most early studies regarding the COX enzymes 
and ovarian cancer focused on COX-2, possibly because of the association of 
COX-2 with carcinomas of various origins (described above) and due to the 
fact that COX-2 was known as the inducible isoform.  Many studies that 
examined COX-2 expression in ovarian cancer indicate that COX-2 is 
expressed in ovarian tumors or some human ovarian cancer cell lines [87-100].  
COX-2 is believed to contribute to tumorigenesis by producing prostaglandins 
that increase cell growth, prevent apoptosis, increase cell motility and 
adhesion, and increase angiogenesis [101].   
The expression of COX-2 in ovarian cancer may not be surprising, 
however, because COX-2 is involved in ovulation and both COX-1 and COX-2 
are normally expressed in the ovary [102].   Some studies, however, found no 
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COX-2 expression in ovarian cancer [103, 104] and others have shown that 
most ovarian cancer cell lines do not express COX-2 [90, 105-107].  One study 
indicated that COX-2 expression is induced by many of the cytotoxic drugs 
used to treat ovarian cancer.  They used tumor samples from individuals that 
had not undergone previous chemotherapeutic treatment and found no COX-
2 expression [105].  This indicates that COX-2 expression may be induced by 
chemotherapy and therefore may not be involved in ovarian tumor formation.  
Furthermore, studies using ovarian cancer cell lines show that the few lines 
that express COX-2 do not respond to cytokines and lose the ability to 
stimulate a normal inflammatory response that is observed in normal OSE 
cells [108, 109].  It is hypothesized that ovarian cancer cells may inactivate 
COX-2 in order to decrease inflammation in an effort to avoid immune 
surveillance [108]. 
COX-1 was largely overlooked in earlier studies of ovarian cancer.  A 
study by Dore et al. in 1998 [103] was the first to show COX-1 but not COX-2 
expression in human ovarian adenocarcinomas.  In 2003, a second group 
verified these findings and also showed COX-1 expression in a human ovarian 
cancer cell line [105].  Since then, COX-1 expression has been further verified 
in human ovarian tumor samples and cell lines [90, 91, 93, 94, 96, 107, 110-113].  
Additionally, a rat model of epithelial ovarian cancer correlated COX-1 with 
ovarian tumors [114] and mouse models of ovarian cancer also correlate COX-
1 with ovarian cancer rather than COX-2 [115, 116].  Although the exact 
contribution of COX-1 to ovarian cancer remains undefined, a recent paper 
suggests that COX-1 may be acting through the PPARδ-ERK signaling 
pathway to contribute to epithelial ovarian cancer through the stimulation of 
cell proliferation  [116].  COX-1 derived prostaglandins may also contribute to 
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ovarian cancer and studies have specifically correlated COX-1 and PGE2 in 
ovarian cancer [107, 110].  PGE2 in particular is believed to be involved in 
ovarian cancer progression due to its involvement with processes such as 
angiogenesis, cell proliferation and apoptosis [50, 51, 96, 105], and the ability 
of PGE2 to stimulate proliferation and reduce apoptosis in EOC cells has been 
confirmed [117]. 
The similarity of sequences for COX-1 and COX-2 and the fact that 
COX-1 expression in ovarian cancer was not considered until recently raises 
the question of whether antibodies used for studies that only considered COX-
2 cross-reacted with COX-1 to give false-positive results.  This, in addition to 
the fact that COX-2 is induced by many chemotherapeutic agents [105], 
suggests that COX-1 may play a significant role in ovarian cancer.  Conflicting 
results in different studies could also be due to differences in detection 
methods used or differences in tissue processing [105].  KO animal models 
have suggested that the normal biological functions of COX-1 and COX-2 are 
not as distinct as was once believed.  Therefore, it should not be surprising 
that both COX enzymes may be involved in cancer development and 
progression.  The possibility that one isoform may be able to compensate for 
the other [108] additionally warrants examination of both isoforms in studies 
of tumorigenesis.  Future studies in this area will hopefully elucidate the exact 
role of the COX enzymes in ovarian cancer initiation and/or progression.  
 
The Role of Vascular Endothelial Growth Factor in Ovarian Cancer 
The hypothesis that tumor cells secrete a factor that increases the 
permeability of blood vessels was presented in 1979 [118] and vascular 
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permeability factor (VPF) was identified in 1983 in the ascites of rodent 
tumors [119].  A few years later a protein with selective mitogenic activity for 
endothelial cells, called vascular endothelial growth factor (VEGF), was 
isolated and it was established that VEGF and VPF were the same protein 
[reviewed in [119]].  VEGF plays a key role in normal ovarian processes 
including follicle development and selection, ovulation, and corpus luteum 
formation [121].  In 1993, a study identified the presence of VEGF in human 
ovarian adenocarcinoma effusions [122] and one year later the constitutive 
expression of VEGF in normal and neoplastic human ovaries was 
characterized [123].   
It has been shown that 97% of ovarian cancers express VEGF and there 
is a significant increase in VEGF expression in stage III and stage IV tumors as 
compared to ovaries without ovarian cancer [124, 125].  Furthermore, a 
significant correlation between ovarian tumor VEGF expression and disease 
stage, histological grade, and patient survival has been found [126-128].  In 
addition to ovarian tumor expression, VEGF expression has been correlated 
with ascites formation associated with advanced ovarian cancer.  As described 
by Nagy et al. [129], the mechanism that links VEGF to ascites formation 
involves the ability of VEGF to stimulate increased permeability of vessels 
lining the peritoneal cavity.  Hyperpermeability of these vessels leads to the 
release of a plasma exudate that nourishes the malignant cells within the 
ascites [129].  VEGF released by malignant cells within the peritoneum 
therefore serves a parallel purpose to VEGF released by solid tumors, to 
increase angiogenesis for nourishment of (and waste removal from) the solid 
tumor.  The concentration of VEGF in ascites has been shown to correlate to 
tumor stage and ascites volume, and negatively correlate to patient survival 
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[128].  
Studies aimed at determining the prognostic significance of the 
concentration of VEGF in the serum of ovarian cancer patients have produced 
mixed results.  It has been reported that serum levels of VEGF were 
significantly increased in patients with ovarian cancer as compared to 
unaffected patients, and patients with metastatic ovarian cancer have 
increased serum VEGF levels as compared to patients with localized tumors 
[130].  Preoperative serum VEGF levels in women with invasive epithelial 
ovarian cancer were also shown to be increased as compared to women with 
low malignant potential ovarian cancer or benign ovarian tumors [131].  Other 
studies, however, found no difference in serum levels of VEGF between 
patients with ovarian carcinoma and those with benign ovarian dysplasia or 
lacking gynecological disease [128, 132].  The contradiction in results 
regarding the usefulness of serum VEGF as a prognostic tool leaves the 
question of whether VEGF can be used to screen women for ovarian cancer 
unanswered. 
The prognostic significance of VEGF expression in ovarian tumors and 
ascites of patients with ovarian cancer, and the possible significance of VEGF 
in the serum of ovarian cancer patients have sparked investigations into 
antiangiogenic treatments targeting VEGF.  The types of anti-angiogenic 
treatments available include bevacizumab (a monoclonal antibody that blocks 
the interaction between VEGF and its receptor), receptor decoys that intercept 
VEGF such as VEGF-Trap, small molecule inhibitors that inhibit receptor 
tyrosine kinases for VEGF, and ribozyme (angiozyme), which targets pre-
mRNA for VEGF receptors [133].  Studies show that inhibition of VEGF 
reduces both ascites formation and ovarian tumor burden [134-138].  These 
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results raise interest in determining the pathways associated with VEGF 
expression in ovarian cancer.   
Interestingly, a link between VEGF and the COX pathways has been 
found in ovarian cancer studies.  A correlation between COX-2 and VEGF 
expression in ovarian cancer has been reported by a number of studies [93, 98, 
100, 139, 140], while less data are available for COX-1.  Lack of data associating 
COX-1 with VEGF may be because COX-1 was overlooked in early ovarian 
cancer studies, as was described above.  One study that considered both COX 
isozymes showed that both COX-1 and COX-2 selective inhibitors could 
decrease endothelin-1 induced VEGF production in human ovarian cancer 
cells [94].  Additionally, VEGF mRNA in human ovarian cancer tissue was 
localized to regions expressing high levels of COX-1 mRNA and a COX-1 
specific inhibitor decreased VEGF production by an ovarian cancer cell line, 
while a COX-2 specific inhibitor did not [105].  These combined data suggest 
that COX-derived prostaglandins may contribute to ovarian cancer 
progression through stimulation of VEGF, which in turn stimulates 
neovascularization and angiogenesis.  Targeting the COX pathways in ovarian 
cancer treatments may therefore decrease ascites burden and tumor growth by 
decreasing VEGF production.   
 
NSAIDs as Chemopreventative/Chemotherapeutic Agents 
Ovarian cancer is the most fatal gynecologic malignancy due in part to 
lack of effective screening techniques to detect early cases and inadequate 
treatment options for patients with advanced stages of the disease.  Factors 
such as these make research of chemoprevention and chemotherapy options 
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for women with ovarian cancer particularly important. Because of the 
association of the COX enzymes and cancer, described above, it is of interest 
to determine whether NSAIDs may aid in the prevention or treatment of 
ovarian cancer. 
Evidence suggests that frequent use of common NSAIDs may aid in the 
prevention of carcinogenesis in tissues such as colon, breast, and pancreas 
among others [141-144].  Additionally, epidemiological studies have indicated 
that the use of aspirin or other nonselective NSAIDs may be associated with a 
risk reduction for ovarian cancer [28-31]. Because of the fact that many of the 
common NSAIDs that are classified as nonselective are generally better 
inhibitors of COX-1 than COX-2 [145], these data support the idea that COX-1 
may play an important role in the development of ovarian cancer. 
Most NSAIDs inhibit the COX enzymes through reversible or 
irreversible binding to the active site of COX enzymes, thus blocking the entry 
and binding of arachidonic acid.  Aspirin is an exception.  Aspirin acetylates a 
serine residue (Ser530 in COX-1 and Ser516 in COX-2) in the channel that leads 
to the active sites of COX-1 and COX-2 [reviewed in [146]], which causes 
irreversible inhibition of the cyclooxygenase but not the peroxidase activity of 
the enzymes [147].  Aspirin is therefore considered a nonselective NSAID 
because it inhibits both COX-1 and COX-2, although it is a more potent 
inhibitor of COX-1 than COX-2 [148].  COX-1 specific NSAIDs block the entry 
of arachidonic acid into the COX-1 active site but do not effectively block the 
entry of arachidonic acid into the larger active site of COX-2.  COX-2 specific 
NSAIDs take advantage of the fact that the active site of COX-2 has a 
hydrophobic pocket not present in the active site of COX-1 and is larger than 
the active site of COX-1, due to a residue difference within the active site as 
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well as other residue differences that line the active site [149].  
The development of COX-specific NSAIDs permitted studies focused 
on the independent contributions of the COX isoforms to ovarian cancer.  One 
study showed that the COX-1 selective inhibitor, SC-560, significantly 
inhibited PGE2 formation and VEGF secretion in human ovarian cancer cell 
lines while the COX-2 selective inhibitor, celecoxib, had no effect [105].  It 
should be noted, however, that the cell lines used do not express COX-2 [105].  
Another study indicated that the use of celecoxib, a COX-2 selective inhibitor, 
had little effect on ovarian tumor growth, while the COX-1 selective inhibitor, 
SC-560, reduced the growth of ovarian tumors [104].  A number of studies 
have reported the effectiveness of selective COX-2 inhibitors in reducing 
growth of human ovarian cancer cell lines [111, 150, 151].  These results again 
may be surprising in light of the fact that the cell lines used in these studies, 
namely OVCAR-3, SCOV-3 and Caov-3, have been shown to lack COX-2 
protein expression [90, 105, 106].  Denkert et al. [113] showed that even though 
COX-2 expression was inducible in OVCAR-3 cells after stimulation with 
interleukin-1β, the same was not true for SKOV-3 cells.  They also found that a 
COX-2 specific inhibitor, NS-398, significantly decreased cell proliferation in 
both OVCAR-3 and SKOV-3 cell lines.  Using siRNA for both COX enzymes, 
they further verified that NS-398 decreased cell proliferation through a COX-
independent mechanism [113].  Another study by Bijman et al. [106] verified 
that the antitumor effects of a selective COX-2 inhibitor, celecoxib, on ovarian 
cancer cell lines occurs in the absence of COX-2 expression.  They also studied 
the intriguing effect of celecoxib catalyzing cisplatin resistance and noted that 
this effect is also independent of COX-2 expression [106].  Results showing 
that celecoxib is more effective at inhibiting cell growth and inducing 
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apoptosis in SKOV-3 cells with wild-type p53 as compared to SKOV-3 cells 
with null type p53 suggest that the COX-independent effects of celecoxib may 
involve the p53 pathway [152].  It is not clear from these studies how COX-2 
selective inhibitors are causing effects in ovarian cancer cells.  Importantly, the 
fact that celecoxib may also decrease the efficacy of chemotherapeutic drugs 
[106] warrants more research before these drugs are used in ovarian cancer 
treatments.   
Explanations for the effectiveness of NSAIDs in the absence of COX-1 
or COX-2 have been proposed.  The presence of COX-1 variants, including 
COX-3, that are affected by NSAIDs is one possibility for alternate targets 
[153].  Other known mechanisms of action of NSAIDs include the ability to 
inhibit calcium movement, enhance intracellular levels of cyclic AMP, inhibit 
NF-κB, and inhibit phospholipase C [reviewed in [154]].   With respect to 
ovarian cancer, studies have shown non-COX actions of NSAIDs that include 
the depletion of cellular thiols, up-regulation of the antitumorigenic protein 
NSAID activated gene -1 (NAG-1), inhibition of macrophage migration 
inhibitory factor, and suppression of NF-κB activity [155-157].  Any of these 
mechanisms working alone or in combination with decreased prostaglandin 
synthesis could account for the anti-cancer effects of NSAIDs [154]. 
 
The Hen as a Model for Ovarian Cancer 
 One of the main impediments to the advancement of ovarian cancer 
research has been the lack of a suitable animal model.  Mice do not 
spontaneously develop ovarian cancer at a rate high enough to study and 
spontaneous tumors in mice differ histopathologically from most tumors in 
 26 
women [158].  Several genetically engineered mouse models of human ovarian 
cancer have been developed, however.  Orsulic et al. [159] found that when 
any two of the oncogenes, c-myc, K-ras, or akt, were introduced in transgenic 
mice deficient in p53, the mice developed ovarian cancer with similar origin, 
progression, and intraperitoneal metastatic spread as human ovarian cancer.  
Another rodent EOC model was developed through the introduction of an 
engineered DNA fragment that placed the oncogene SV40 T antigen 
downstream of the mullerian inhibiting substance type II receptor promoter, 
which restricted expression of the oncogene to the ovary [160].  Mice in this 
model developed ovarian tumors in ~50% of cases.  Inactivation of p53 and 
Rb1 by intrabursal administration of recombinant adenovirus expressing Cre 
was also found to effectively induce EOC in mice [161].  Wu et al. [162] 
developed a more recent mouse model by deregulating the PI3K/Pten and 
Wnt/beta-catenin signaling pathways.  Greater than 75% of mice in this model 
developed adenocarcinomas morphologically similar to human ovarian 
endometroid adenocarcinoma, with similar biological behavior and gene 
expression patterns [162].   
The induction of genetic alterations to initiate ovarian cancer in mice 
may be introducing changes that do not accurately portray the spontaneous 
etiology of ovarian cancer.  A model that spontaneously develops EOC may 
more accurately depict the pathogenesis of the disease in women.  Most 
animals, however, do not spontaneously develop ovarian cancer [158, 163], 
possibly due to the fact that the common natural reproductive state of most 
animals is pregnancy or lactation.  It has also been suggested that human OSE 
cells are incompletely committed and arrested in a progenitor state, unlike the 
OSE of laboratory animals, which may make these cells in humans more prone 
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to neoplastic transformation [8, 164].  The interaction between the OSE and the 
extracellular matrix in women may contribute to the phenotypic plasticity of 
OSE cells, which enables these cells to perform the diverse functions for the 
maintenance and remodeling of the dynamic ovarian cortex [165].  Another 
major difference between human OSE cells and those of laboratory animals is 
the connection between the cells and the underlying tissues.  OSE cells in 
women are loosely attached to the underlying tunica albuginea, which 
separates the OSE from the ovarian stroma and partially inhibits the transfer 
of bioactive materials between the stroma and the OSE [8].  The OSE of rats 
more firmly adheres to the ovarian stroma, which may expose these cells to a 
different microenvironment [164].  Exposure of the OSE in women to the 
ovarian stroma in the form of inclusion cysts, therefore, may be a more drastic 
environmental change that permits neoplastic progression as compared to 
exposure of rodent OSE cells to the ovarian stroma.  While studying the 
differences between humans and animals that do not frequently 
spontaneously develop EOC (including nonhuman primates [reviewed in 
[166]] may provide insight into protective effects for the disease, a 
spontaneous model of ovarian cancer may prove invaluable to investigating 
the underlying events preceding ovarian carcinogenesis. 
The laying hen (Gallus domesticus) is a persistent ovulator and 
spontaneously develops ovarian adenocarcinomas [167-170].  In an analysis of 
the hen as a model of ovarian cancer in 1987, Fredrickson found an ovarian 
tumor incidence of 32% in 466 hens studied for 3.5 years ranging in starting 
age from 2-7 years.  He also determined that ovarian tumors are uncommon in 
hens less than 2 years of age [167].  As explained by Murdoch et al. [17], the 
surface epithelial cells located near a follicular rupture are exposed to 
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oxyradicals that are liberated during ovulation.  They confirmed in the hen 
that there are elevated levels of 8-oxo-guanine adducts in OSE cells collected 
from the apical surfaces of preovulatory follicles and perimeters of 
postovulatory follicles.  A surface epithelial cell with these adducts that 
escapes repair or apoptosis could then give rise to a transformed phenotype.  
These adducts in the hen therefore may be indicative that genomic damage to 
the OSE caused by frequent ovulation is a main contributor to ovarian cancer 
initiation [17].  
The hen reproductive tract normally consists of a single oviduct and 
ovary on the left side of the animal.  The single ovary (Fig. 1-3, A) consists of 
an ovarian cortex in which primordial, primary, and secondary follicles are 
located.  Cortical follicles (<1mm in diameter) are located throughout the 
ovarian stroma.  Protruding from the cortex are several thousand growing, 
non-hierarchical follicles ranging from small white follicles (~1mm in 
diameter) to small yellow follicles (~6-10mm in diameter).  The largest 
protruding follicles are organized into a hierarchy identified as F6 through F1.  
The F1 is the next follicle to ovulate, which is initiated at the stigma, and the F2 
follicle ovulates roughly 24 hours later.  Tumorigenesis in the hen ovary (Fig. 
1-3, B) is characterized by disruption or complete loss of the ovarian hierarchy.  
In these cases, the non-cortical follicles are replaced by cauliflower-like 
nodules, fluid-filled cysts and/or hemorrhagic follicles.   
Ovarian cancer in the hen morphologically and histopathologically 
resembles the human disease [167, 171-174].  As mentioned previously, 
cauliflower-like nodules are commonly found within or extending from the 
cortex of the ovary and glandular-like areas are present in histological sections 
of ovarian tumors.  Similar to humans, metastases to other organs within the  
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A normal hen ovary (A) consists of follicles ranging in size from small white 
follicles (SWF), large white follicles (LWF), small yellow follicles (SYF), and a 
hierarchy of large yellow follicles (labeled F5 to F1).  Disruption of the ovarian 
hierarchy and cauliflower-like nodules (B, arrow) are typical of ovarian 
tumors in the hen (B).      
 
 
 
A B 
Figure 1-4.  Example of a normal hen ovary (A) and an ovarian tumor 
(B). 
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peritoneal cavity are often associated with ovarian cancer progression [175], 
with metastasis to the oviduct, intestinal tract, and liver being most common.  
Additionally, metastasis is rarely found outside the peritoneal cavity in 
women [176, 177] as well as in hens [178].  Also similar to humans, the 
development of ascites within the peritoneal cavity of hens is associated with 
advanced cases of ovarian cancer [179].   
Although several studies from 1941-1969 reported the occurrence of 
ovarian adenocarcinoma in hens [168-170, 180, 181], it was not until 1987 that 
Fredrickson published his landmark study of ovarian cancer incidence in 
hens.  Following this, it was not until 2001 that studies began to evaluate the 
validity of the hen as a model for a mammalian carcinoma.  Rodriguez-
Burford et al. [171] identified expression of antigens in hen ovarian tumors 
using antibodies made against human antigens.  These included cytokeratin 
AE1/AE3 and pan cytokeratin (epithelial markers); EGFR and erB-2 
(epidermal growth factor receptors); and Lewis Y, CEA, and Tag 72 (oncofetal 
tumor markers).  Additionally, antibodies that stain surrogate endpoints for 
human ovarian cancer that cross-reacted in the chicken include PCNA 
(marker of proliferation), p27 (cell cycle inhibitor), and TGF-∝ (growth factor 
receptor).  This study suggested that the hen may be a useful model to study 
the efficacy of chemopreventative agents [171].   
The first study to isolate and culture chicken OSE cells was complete by 
Giles et al. [172], which further developed the hen as a model for ovarian 
adenocarcinoma.  This study also verified positive expression of cytokeratin 
and PCNA in hen ovarian tumors and cultured OSE cells, and determined the 
expression of progesterone receptor (PR) within these samples.  PR 
immunohistochemical staining in OSE cells was similar in the chicken to what 
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is observed in humans.  Expression of PR in the tumors of hens may also 
suggest that tumors in hens are hormone-responsive [172].   
The origin of ovarian adenocarcinoma in hens was addressed in a study 
that determined the expression of an oviductal protein, ovalbumin, in ovarian 
samples collected from 12 hens with adenocarcinoma because of the 
observation that many advanced peritoneal cancers in hens involved both the 
ovary and the oviduct.  The presence of ovalbumin in the ovary of all 12 hens 
was interpreted as indicating that most adenocarcinomas in hens are oviductal 
in origin [182].  It should be noted that oviductal lesions were also observed in 
all 12 hens used in the study.  Interestingly, it has also been suggested that a 
higher percentage of cases of ovarian cancer in women may actually have 
fallopian origin than was originally believed [183].  Twenty years after 
Haritani et al. [182], Giles et al. [184] demonstrated that ovalbumin was 
expressed in ovarian tumors of the hen that lacked oviductal involvement.  
This result was interpreted as suggesting that ovarian tumor cells 
dedifferentiate during tumorigenesis and therefore resemble serous (fallopian 
tube-like) tumors in humans [184].  This finding was particularly useful in 
validating the hen as a model for human ovarian cancer in light of the fact that 
serous tumors are believed to be the most common type of ovarian tumors in 
women.  
Fredrickson’s original study in 1987 showed a difference in 
susceptibility to ovarian cancer among different flocks of hens [167].  This 
suggested that there is a level of genetic susceptibility to ovarian cancer in 
hens.  Johnson et al. [185] confirmed a difference between two genetic strains 
of hens and ovarian cancer incidence.  They found a greater incidence of 
ovarian neoplasms in the Cornell C strain of White Leghorn hens than the 
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Cornell K strain hens.  In addition, they found elevated levels of plasma 
estradiol and lower levels of plasma immunoreactive inhibin in the C strain as 
compared to the K strain [185].  This study furthered the understanding of 
differences between strains of hens that may predispose one strain to 
developing ovarian cancer.       
Jackson et al. [186] reported that chicken ovarian tumors express cancer 
antigen 125 (CA125), which is a tumor marker that is found to be elevated in 
blood in many patients with ovarian cancer and is used as a screening agent 
for the disease [187].  They analyzed CA125 expression in dispersed tumor 
cells and ovarian tumors of the hen using immunohistochemical and Western 
blot analyses [186].  Although they did publish the first protocol on tumor 
dispersion in the hen, the data regarding CA125 expression may be 
questionable.   Necessary controls were omitted from immunocytochemical 
analysis and Western blot results indicate the CA125 band at a size that is 
smaller from the expected size.  Furthermore, it was previously determined 
that CA125 is not expressed in ovarian tumors of the hen [171] and no study to 
date (including unpublished reports from our lab) has confirmed the findings 
of Jackson et al. [186].   
Recently, an increase in the expression of COX-1 mRNA in ovarian 
tumors as compared to normal hen ovaries was shown [188], which confirmed 
an earlier study from our lab [189].  Both studies showed no difference in 
COX-2 expression between normal ovaries and ovarian tumors.  The more 
recent study of COX expression [188] also found a significantly increased 
expression of COX-1 mRNA in the first post-ovulatory follicle (POF-1) as 
compared to POF-2 or POF-3, and no difference in COX-2 expression among 
POFs.  The expression of COX-1 in POFs is interesting in light of the 
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hypothesis that the POF could serve as a potential site for the formation of 
clefts or inclusion cysts and subsequent incorporation of OSE into the ovarian 
stroma [188].  No difference in COX-1 or COX-2 mRNA in the OSE isolated 
from individual follicles in the hierarchy was found [188}.  This study 
therefore confirmed and expanded the previous characterization of the COX 
enzymes in the hen ovary. Finally, in 2008, the expression pattern of selenium-
binding protein 1, an important mediator of the anti-cancer effects of 
selenium, in the hen was shown to parallel that found in women with ovarian 
cancer [174].   
Most studies using the hen model of ovarian cancer have focused on 
validation of the model by determining expression patterns of genes and 
proteins associated with the etiology of the disease in women, as described 
above.  Only two studies to date have moved beyond validation of the hen 
model and have begun to utilize hens to study early detection or prevention 
methods.  One study that evaluated the effectiveness of medroxyprogesterone 
acetate (Depo-Provera) as a chemopreventative agent in the hen model of 
ovarian cancer found evidence of reduced incidence of adenocarcinoma in the 
Depo-Provera group as compared to control [190].  This evidence may be 
considered comparable to the reduced incidence of ovarian cancer observed 
with oral contraceptive use in women.  It should be noted that only a partial 
reduction in ovulation was achieved, the hens were only treated for one year, 
and the data indicate that up to 10% of the hens may have had ovarian cancer 
prior to initiation of the study [190].  A study aimed at utilizing ultrasound as 
a method for early detection of ovarian cancer was reported by Barua et al 
[173].  Their results show that ovarian tumors in the hen can be detected using 
in vivo transvaginal sonographic techniques.  They additionally showed that 
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blood flow velocity increased in ovaries of hens with malignant tumors [173].  
The ability to non-invasively identify hens with tumors permits hens to be 
utilized to test the efficacy of chemopreventative or chemotherapeutic 
reagents.   
The main objective of the work presented in this dissertation was to 
study the potential role of the COX enzymes in ovarian cancer in the hen as a 
model for the human disease.  The mRNA and protein expression of the COX 
enzymes and VEGF was determined in normal ovaries and ovarian tumors of 
the hen, as well as ascites cells collected from hens with ovarian tumors.  The 
efficacy of several NSAIDs to decrease VEGF expression and to affect the 
viability of ascites cells was also examined in subsequent in vitro studies.  
Finally, the in vivo effects of feeding hens a diet containing aspirin, a common 
NSAID, on ovarian cancer incidence and progression were determined.   
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CHAPTER 2  
CYCLOOXYGENASE 1 AND 2 mRNA AND PROTEIN EXPRESSION IN THE 
GALLUS DOMESTICUS MODEL OF OVARIAN CANCER* 
Abstract 
Objective.  Our purpose was to determine the mRNA and protein 
expression of cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) in 
ovarian tumors and normal ovaries of the hen, which is an excellent model for 
human ovarian cancer.   Tissue concentrations of prostaglandin E2 (PGE2) and 
PGE2 metabolites were also determined. 
Methods.  Tissue was obtained from ovarian tumor (n=18) and normal 
ovary (n=29) of 2-4-year old Single-comb White Leghorn hens.  Quantitative 
real-time PCR with Sybr Green was used to quantify the mRNA expression of 
COX-1 and COX-2, using 18S expression as an internal control for COX 
normalization.  Immunohistochemistry using antibodies for COX-1 and COX-
2 was used to localize protein expression of each isoform in a subset of tumor 
(n=5) and normal samples (n=6).  For determination of tissue prostaglandin 
concentration, tissue was obtained from ovarian tumor (n=8) and normal 
ovary (n=8).  PGE2 and PGE2 metabolites were measured using competitive 
enzyme immunoassays (EIAs). 
 Results.  Our results indicate that COX-1 mRNA expression is 
                                                 
* This article was published in Gynecologic Oncology, 103(2), ME Urick and PA 
Johnson, Cyclooxygenase 1 and 2 mRNA and protein expression in the Gallus 
Domesticus model of ovarian cancer, 673-678, Copyright Elsevier (2006). 
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significantly higher (p< 0.05) in ovarian tumor samples compared to normal 
ovaries while there is no significant difference in expression of COX-2 between 
the samples.  Immunohistochemistry results support this finding and show 
COX-1 expression only in tumor samples and COX-2 expression unchanged 
between normal ovary and tumor samples.  PGE2 levels are significantly 
higher (p<0.05) in tumor samples compared to normal ovaries and there is no 
significant difference in PGE2 metabolite levels between the samples. 
Conclusion.  These findings may implicate COX-1 as a suitable target for 
the prevention or treatment of ovarian cancer.  
 
Introduction 
 Ovarian cancer continued to be one of the leading causes of death due 
to cancer in women in 2005 [1].  More than 85% of human ovarian cancers are 
believed to arise from the ovarian surface epithelial layer [2].  These epithelial 
ovarian cancers are characteristically heterogenous in nature and insights into 
the underlying molecular and genetic events leading to ovarian 
adenocarcinoma are still largely unknown.  One of the main impediments to 
the advancement in ovarian cancer research has been the lack of a suitable 
animal model for spontaneous ovarian cancer.  Mouse models may be 
considered inefficient due to lack of spontaneous cancer occurrence [3] and 
more recent models in which genetic alterations are induced to cause ovarian 
cancer [4-6] may be introducing changes that do not accurately portray 
spontaneous development of ovarian cancer.  The laying hen (Gallus 
domesticus) has proved to spontaneously develop epithelial ovarian 
adenocarcinomas similar to the human female with a fairly high incidence [7, 
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8, 9].  The hen has thus provided a spontaneous model to study the etiology 
and/or treatment of ovarian cancer. 
The cyclooxygenase (COX) enzymes are key rate-limiting enzymes 
responsible for catalyzing the synthesis of prostaglandins from arachidonic 
acid.  Two isoforms currently being studied with respect to cancer risk are 
COX-1 and COX-2.  Separate genes encode COX-1 and COX-2 and the two 
isoforms have distinct expression patterns. Evidence suggests that the COX 
enzymes may be involved in both the establishment of tumors [13] and 
maintenance of existing tumors [14].  The role of the COX enzymes in ovarian 
cancer, however, remains unknown and conflicting evidence has been 
published regarding the expression of both isoforms in human ovarian 
tumors.  Past studies have associated COX-2 expression with carcinogenesis 
including that of the lung, colon, breast, head and neck [15, 16, 17].   For this 
reason, most studies of ovarian tumor formation focused on COX-2 expression 
and COX-1 has been largely overlooked in studies of ovarian cancer [14].  
Although a number of studies have shown increased COX-2 expression in 
ovarian tumors or a subset of tumors, other studies indicate that COX-2 is 
overexpressed in preneoplastic lesions rather than established ovarian tumors 
[10,18].  Conflicting results may be due to case selection or differences in the 
detection method, tissue processing, or specificity of the antibody used.  
Recent studies also indicate that ovarian cancer exhibits increased expression 
of COX-1, rather than COX-2 [14, 19, 20] and other studies that considered 
COX-1 [10, 18, 21, 22], found positive expression in human ovarian cancer.  
These data combined with the fact that some studies found no COX-2 
expression in ovarian cancer [14, 19, 20] suggest that COX-1 may be more 
highly correlated with ovarian adenocarcinoma than COX-2.   
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The reactions catalyzed by COX-1 and COX-2 produce a number of 
lipids known as prostaglandins.  Increased prostaglandin levels have been 
associated with many of the major types of cancer, although the role of 
prostaglandins in the pathology and progression of these cancers is not certain 
[23].  Prostaglandins are thought to contribute to carcinogenesis through the 
enhancement of cell growth, inhibition of apoptosis, and modulation of the 
immune system, and have also been associated with increased cell 
proliferation, enhanced tumor invasiveness, and metastatic potential [23, 24, 
25].  The production of stable oxy radicals and the formation of 
malondialdehyde are both catalyzed by prostaglandins and both may lead to 
the formation of mutations that may eventually trigger tumor formation [23].  
A recent paper reported that COX-1 was the prominent pathway responsible 
for prostaglandin production in a genetically modified mouse model of 
epithelial ovarian cancer [14].  Studies have indicated that prostaglandin E2 
(PGE2), in particular, is elevated in ovarian cancer [25, 26].  For this reason, we 
focused on PGE2.  The goal of the following experiment was to assess the 
abundance of COX-1 and COX-2 mRNA in normal ovarian tissue as well as in 
ovarian tumor samples of the hen and to localize COX-1 and COX-2 protein 
using immunohistochemistry.  Concentrations of PGE2 and PGE2 metabolites 
were also determined using competitive enzyme immunoassays (EIAs). 
 
Materials and Methods 
Tissue Samples.  Ovarian tumor (n=18) and normal ovarian (n=29) tissue 
samples were collected from 2-4-year old Single-comb White Leghorn hen 
ovaries for PCR analysis and a subset of these samples was used for 
 64 
immunohistochemistry (ovarian tumor n= 5; normal ovary n= 6).  Tissue was 
also collected from ovarian tumors (n=8) and from normal ovaries (n=8) of 2-
5-year old Single-comb White Leghorn hen ovaries for PGE2 and PGE2 
metabolite EIA analysis.  Diagnosis was made by histopathologic analysis of 
hematoxylin and eosin sections.  
 RNA Extraction.  RNA was extracted from hen ovarian tissue using the 
RNeasy Mini Kit (Qiagen) and integrity was verified through use of 2100 
Expert Bioanalyzer (Agilent Technologies).  Extracted RNA was subjected to 
reverse transcription to cDNA. 
       PCR Analysis.  Quantitative real-time PCR with Sybr Green was used to 
quantify the expression of each COX isoform, using 18S expression as an 
internal control for COX normalization.  Chicken-specific primers designed to 
span intron regions were used and predicted a product of 74 bp for COX-1 
(forward: 5’TGGCGGAGTCCTTTTCCATG3’; reverse: 
5’TTAATGCCAACGTACTGGGA3’) and 88 bp for COX-2 (forward: 
5’CTCGTGCAAGTGGAACTCGT3’; reverse: 
5’GAGGTGTATGCATGACAACA3’).  Control reagent was Ambion Quantum 
RNA Universal 18S primers (# 1718) and controls were run for each sample.  A 
standard curve was established from a pool of the RNA of 5 normal hen 
ovaries, which was reverse transcribed to cDNA.  Control reactions lacking 
reverse transcriptase and template were also run on each plate.  Reactions 
were 50 µl in total volume consisting of a final concentration of 1x Quantitect 
SYBR Green PCR Master Mix (Qiagen), 0.3 µM of COX primer or 0.2 µM of 
18S primer solution, 4 µM Rnase-free water, and 0.4 µM cDNA.  All sample 
amplifications were run in duplicate using an ABI Prism 7000 Sequence 
Detection System and the mean value was calculated relative to 18S reactions.  
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Sequence Detection System Software (Applied Biosystems) was used to 
determine mRNA concentration. 
Immunohistochemistry.  Polyclonal rabbit anti-mammalian COX-1 
antibody was purchased from Oxford Biomedical Research Inc. (# PG 20) and 
rabbit polyclonal anti-chicken COX-2 antibody was generously donated by 
Oxford Biomedical Research Inc.  Paraffin sections were deparaffinized and 
rehydrated through a series of xylene and ethanol treatments.  Antigen was 
retrieved through heating in citrate buffer (COX-1) or incubation at 37 °C with 
pronase (COX-2).  Sections were blocked with 10% goat serum in PBS for 30 
minutes at 37 °C and treated with primary and secondary antibodies for 1 
hour at 37 °C.  Control slides were treated with normal rabbit IgG (Upstate 
Self Signaling Solutions #12-370).  All primary antibodies were diluted 1:25.  
The secondary antibody was Alexa Fluor 488 goat anti-rabbit IgG conjugate 
(Molecular Probes #A-11034) diluted to 1.3 µg/mL.  Slides were viewed using 
a Nikon eclipse E600 microscope with fluorescence capability and images 
were captured using a SPOT RT Slider camera with a standardized exposure 
of 6 sec. 
 PGE2 Competitive Enzyme Immunoassay (EIA).  PGE2 and PGE2 
metabolites were extracted according to manufacturer’s protocol (Cayman 
Chemical) and measured using the PGE2 EIA Kit (# 514010) and PGE 
metabolite EIA kit (# 514531), respectively.  Concentrations (pg/mL) were 
estimated from the absorbance of the calculated standard curve.  Results were 
calculated using the Cayman Chemical computer spreadsheet.  
 Statistics.  All data were analyzed with SAS using Proc GLM and the 
significance level was P < 0.05.  Duncan’s multiple range test was used to 
separate means.   
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Results 
Quantitative Real-Time PCR.  Figures 2-1 and 2-2 show results of 
quantitative real-time PCR for COX-1 and COX-2 mRNA expression, 
respectively.  After normalization to 18S expression, results indicate that COX-
1 expression was significantly increased in ovarian tumor samples as 
compared to normal ovarian samples (p< 0.05).  No significant difference in 
COX-2 expression was observed between ovaries with tumors and normal 
ovaries.  Figure 2-3 indicates that the ratio of COX-1 expression to COX-2 
expression was significantly higher in ovarian tumor samples as compared to 
normal ovarian samples (p< 0.05). 
 Immunohistochemistry.  Figure 2-4 shows representative 
photomicrographs of immunohistochemistry results of normal ovary and 
ovarian tumor samples.  Panels A and B show representative hematoxylin and 
eosin stains.  Normal ovary sections indicate the presence of follicles (panel 
A), while ovaries with tumors typically have fewer follicles than normal 
ovaries and have glandular-like structures within the ovary (panel B).  Normal 
ovary showed no specific COX-1 staining (panel C) as compared to the control 
adjacent section (panel E).  COX-1 specific staining was observed within the 
glandular structures of ovarian tumor (panel D) as compared to the IgG 
control (panel F).  Widespread COX-2 specific staining was observed in 
normal ovary (panel G) as compared to adjacent section control (panel I) and 
ovarian tumor (panel H) as compared to adjacent section control (panel J).  All 
tumor samples (n=5) and normal ovary samples (n=6) showed the same 
expression pattern. 
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Asterisks indicate a significant increase in ovaries with tumors as 
compared to normal ovaries (p<0.05).  Bars indicate standard error. 
 
Figure 2-1.  COX-1 mRNA expression in ovaries with tumors 
and normal ovaries.   
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    No significant differences were found.  Bars indicate standard error. 
 
Figure 2-2.  COX-2 mRNA expression in normal ovaries and 
ovaries with tumors.   
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Asterisks indicate a significant increase in ovaries with tumors as compared to 
normal ovaries (p<0.05).  Bars indicate standard error. 
Figure 2-3.  Ratio of COX-1/COX-2 mRNA expression in normal ovaries 
and ovaries with tumors.   
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Normal ovary and ovarian tumor stained with Hematoxylin & Eosin (A, B), 
COX-1 antibody (C, D), normal rabbit IgG (E, F), COX-2 antibody (G, H), and 
normal rabbit IgG (I, J). COX-1 staining is observed only in ovarian tumor. 
Positive COX-2 staining is observed in both normal ovary and ovarian tumor. 
 
Figure 2-4.  COX immunohistochemistry results.  
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PGE2 Competitive Enzyme Immunoassay (EIA).  Results in Figure 2-5 
show that PGE2 levels are significantly increased in ovarian tumor as 
compared to normal ovarian samples (p<0.05).  No significant difference in 
PGE2 metabolite levels was observed between the samples (Figure 2-6).  
 
Discussion 
Our quantitative real-time PCR analysis indicates that COX-1 mRNA is 
elevated in hen ovarian tumor samples as compared to normal hen ovarian 
samples.  These results were supported by our immunohistochemistry results, 
which showed specific COX-1 staining in glandular areas within the ovaries 
with tumors.  The localization of COX-1 only to the glandular areas of ovaries 
with tumors could explain the large standard error associated with COX-1 
mRNA expression (Fig. 2-1).  Samples for quantitative PCR were taken at 
random from the main body of the ovaries with tumors, which could have 
resulted in variability in the amount of glandular areas included in the PCR 
analysis for each sample.  COX-1 expression was undetectable by 
immunohistochemistry in normal ovary, presumably due to low abundance.  
These results suggest that a correlation exists between COX-1 expression and 
ovarian tumors of the hen.   
We found no correlation between COX-2 expression and ovarian 
tumors.  No difference in COX-2 mRNA expression was observed between 
normal ovaries and ovaries with tumors and widespread COX-2 protein 
staining was observed in both normal ovaries and ovaries with tumors.  
Enhanced COX-2 expression in the ovary may have been due to the relatively  
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Asterisks indicate a significant increase in ovaries with tumors as compared to 
normal ovaries (p<0.05). Bars indicate standard error. 
 
Figure 2-5.  Prostaglandin E2 production in ovaries with tumors and normal 
ovaries.   
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No significant differences were found. Bars indicate standard error. 
 
 
Figure 2-6.  Prostaglandin E2 metabolite production in normal 
ovaries and ovaries with tumors.   
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old age of the hens used.  Studies show that COX-2 expression may increase 
with age [29].  We selected older birds, because hens display increasing 
susceptibility to tumor formation after 2 years of age [8].  It is possible that the 
COX-2 expression levels in this group of hens may be higher than that in 
younger hens.  We have not yet examined COX expression in hens younger 
than 2 years of age.  Studies have shown that in human ovaries, COX-2 
expression is found in follicles prior to ovulation and in interstitial tissue 
following ovulation [31].  The wide-spread COX-2 expression found in this 
experiment in both tumors and normal ovaries could therefore, be associated 
with the frequent ovulation which occurs in the hen. 
Increased expression of COX enzymes generally results in increased 
levels of prostaglandins, which have been correlated to a number of cancers 
[23].  Prostaglandin E2 (PGE2) in particular has been correlated with ovarian 
cancer [25, 26].  The present study indicates that PGE2 concentration is greater 
in hen ovarian tumor samples compared to normal ovary samples.  Because of 
the labile nature of PGE2 and prostaglandins in general, the metabolite levels 
of PGE2 were measured to be sure that there were no differences in the 
metabolism of PGE2 between normal samples and samples with ovarian 
tumors.  No difference in PGE2 metabolite levels was found.  Previous studies 
found that PGE2 induced angiogenesis in chicken embryos [27] and stimulated 
proliferation and inhibited apoptosis in two epithelial ovarian cancer cell lines 
[28].  PGE2 may also suppress immune function, thus leading to increased 
susceptibility to tumor formation and impaired defense against previously 
formed tumors [23].  One recent study indicates that PGE2 production in 
ovarian cancer cell lines is regulated by COX-1 [30].  Specifically, the study 
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showed a correlation between PGE2 production and COX-1 mRNA and 
protein.  Inhibition of PGE2 production was achieved through a selective 
COX-1 inhibitor, while COX-2 inhibitors had no effect.   
Our data suggest that the increase in PGE2 found in hen ovaries with 
tumors may be due to COX-1.  To examine the relative expression of the two 
COX isoforms in these tissues to be sure that COX-2 under-expression was not 
a compensation for COX-1 over-expression, we compared the ratio of COX-1 
to COX-2 in ovaries with tumors to this ratio in normal ovaries.  We found 
that this ratio is higher in ovaries with tumors as compared to normal ovarian 
samples.  Although these data are not relevant to the biologic activity of either 
isozyme, the data do show that minor differences in COX-2 expression do not 
alter the main result of increased COX-1 expression in ovarian tumor samples 
as compared to normal ovaries.  It is therefore plausible that the increase in 
PGE2 in tumor samples is due to the COX-1 pathway. 
    Future studies utilizing non-steroidal anti-inflammatory drugs 
(NSAIDs) in the hen may provide the insight needed to determine whether 
COX-1 is responsible for the increase in PGE2 expression found in ovarian 
tumor samples.  It is not clear from this study whether COX-1 is involved in 
the establishment or in the maintenance of ovarian tumors of the hen.  This 
could also be determined through studies using NSAIDs.  NSAIDs prevent 
prostaglandin biosynthesis through inhibition of the COX enzymes.  Recently, 
NSAIDs have been considered for use in cancer prevention.  One study 
indicates that the use of celecoxib, a COX-2 selective inhibitor, had little effect 
on ovarian tumor growth, while the COX-1 selective inhibitor, SC-560, 
reduced the growth of ovarian tumors [14].  Additionally, a recent population-
based, case-control study showed that the use of NSAIDs, including aspirin, 
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was associated with a reduction in the risk of ovarian cancer [32].  Because of 
the fact that many of the common NSAIDs that are classified as nonselective 
are generally better inhibitors of COX-1 than COX-2 [33], these data suggest 
that COX-1 NSAIDs may be effective at reducing the risk of ovarian cancer.   
Although COX-2 has been implicated in a range of other cancers, our 
results indicate that in the hen, COX-1 mRNA and protein are increased in 
tumors.  Our data also indicate an increase in PGE2 and suggest that this 
increase may be due to COX-1.  Interestingly, supporting evidence for this 
finding was also obtained in a genetically modified mouse model of epithelial 
ovarian cancer [14].  These combined results suggest that COX-1 could be a 
suitable target for the prevention and treatment of epithelial ovarian cancer. 
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CHAPTER 3  
VEGF EXPRESSION AND THE EFFECT OF NSAIDS ON ASCITES CELL 
PROLIFERATION IN THE HEN MODEL OF OVARIAN CANCER* 
Abstract 
Objectives.  We aimed to determine the expression of vascular 
endothelial growth factor (VEGF) and the effect of nonsteroidal anti-
inflammatory drugs (NSAIDs) on the proliferation of cells isolated from 
ascites in the hen model of ovarian cancer.  
 Methods.  Ovarian tumor and normal ovary were collected from hens 
and ascites cells were isolated from hens with ovarian cancer.  Quantitative 
real-time PCR was used to quantify mRNA expression.  Immunohistochemical 
and/or Western blot analyses were used to localize protein expression in 
ovarian tumors, normal ovaries, and ascites cells.  Cells were treated with a 
nonspecific, COX-1 specific, or COX-2 specific NSAID and proliferation was 
determined.    
 Results.  VEGF mRNA was increased in ascites cells and there was a 
trend for a correlation between VEGF mRNA in ascites cells and ascites 
volume.  VEGF protein was localized to theca cells of normal ovaries, in 
glandular areas of tumors, and to the cytoplasm of ascites cells.  Aspirin and a 
COX-1 specific inhibitor decreased the proliferation of ascites cells, whereas a 
COX-2 specific inhibitor did not.  
                                                 
* This article was published in Gynecologic Oncology, 
doi:10.1016/j.ygyno.2008.05.018,  ME Urick, JR Giles, and PA Johnson, VEGF 
expression and the effect of NSAIDs on ascites cell proliferation in the hen 
model of ovarian cancer, Copyright Elsevier (2008).  
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 Conclusions.   VEGF may play a role in ovarian cancer progression in 
the hen and the proliferation of ascites cells can be decreased by targeting the 
COX-1 but not COX-2 pathway.  
 
Introduction 
At diagnosis, nearly 70% of women with ovarian cancer have an 
advanced stage of the disease which has spread beyond the ovaries [1]. 
Advanced ovarian carcinoma is characterized by the accumulation of 
malignant ascites, which is inversely associated with survival [reviewed in 
[2]].  Vascular endothelial growth factor (VEGF) has been correlated to the 
metastasis of ovarian cancer cells as well as to peritoneal ascites accumulation 
[3], and studies have shown that inhibition of VEGF reduces ascites formation 
[4, 5] and ovarian tumor burden [6].  
 Evidence suggests that frequent use of nonsteroidal anti-inflammatory 
drugs (NSAIDs) may aid in the prevention of carcinogenesis in tissues such as 
colon, breast, and pancreas [7-9].  In addition, epidemiological studies have 
indicated that use of NSAIDs is correlated with decreased ovarian cancer risk 
[10-13].  An explanation for the chemopreventative effect of these drugs is 
inhibition of the cyclooxygenase (COX) enzymes.  Interestingly, COX-1 
expression has been correlated with VEGF expression in human ovarian 
cancer.  VEGF mRNA in human ovarian cancer tissue was localized to regions 
expressing high levels of COX-1 mRNA and a COX-1 specific NSAID 
inhibited VEGF production by an ovarian cancer cell line, while a COX-2 
specific NSAID did not [14].   
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The domestic hen spontaneously develops ovarian cancer with many 
similarities to the human disease, including the accumulation of ascites.  We 
determined the expression of VEGF in the hen model of ovarian cancer and 
examined the effects of a nonspecific, COX-1 specific, and COX-2 specific 
NSAID on the proliferation of cells isolated from ascites collected from hens 
with ovarian cancer.  Finally, we aimed to determine the effects of these 
NSAIDs on VEGF expression in ascites cells.  
 
Materials and Methods 
Animals.  White Leghorn hens were individually caged, with free access 
to water and feed and were maintained on a 15 hour light and 9 hour dark 
schedule.  Hens with ovarian cancer were selected from a flock of 
approximately 918 2-7 year-old hens by observation of ascites accumulation 
and palpation and verified by histological examination.  Animal procedures 
were approved by the Institutional Animal Care and Use Committee of 
Cornell University.  
  Sample Collection.  Ascites fluid was aspirated from hens after 
euthanasia (n=15) and cells were isolated using centrifugation.  Results from 
ascites of individual hens were averaged for each experiment.   Ascites 
volume (ml) was determined by subtracting hen body weight (g) after 
removal of total ascites volume from hen weight (g) prior to ascites removal.  
Ovarian tissue was stored in RNAlater (Qiagen) for RNA extraction or fixed in 
buffered formalin for immunohistochemical analysis.     
  Cell Culture.  Cells were isolated from ascites fluid (n=13) and 
resuspended in M199. Ascites cells were plated in 96-well plates at a density of 
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2-4 x 103 cells/well and in 6-well plates or on coverslips at a density of 50 x 103 
cells/well. Cells were maintained in M199 containing 10% FBS and 1% 
penicillin-streptomycin at 37°C in a humidified atmosphere with 5% CO2.  
RNA Extraction.  RNA was extracted using the RNeasy Mini Kit 
(Qiagen), including DNase digestion.  Cell cultures were terminated by 
removal of medium and addition of Buffer RLT (supplied in RNeasy Mini 
Kit).  Cells were collected by gentle scraping and homogenized.  
  Quantitative PCR.  Quantitative real-time PCR with SYBR Green was 
used to quantify the expression of VEGF, COX-1, and COX-2 mRNA, using 
18S rRNA as an internal control (n=6-7).  VEGF primers (designed to span 
introns) were described by Makanya et al. [15] and COX-1 and COX-2 primers 
were described previously [16]. Control reagent was Quantum RNA Universal 
18S primers (Ambion #1718), and controls were run for each sample. A 
standard curve was established from a pool of RNA from 5 normal hen 
ovaries. Control reactions lacking reverse transcriptase or template were run 
on each plate. Reactions were 50 µl in total volume with a final concentration 
of 1× Power SYBR Green PCR Master Mix (Qiagen), 0.3 µM of VEGF primer or 
0.2 µM of 18S primers, and 0.4 µM cDNA. Sample amplifications were run in 
duplicate using an ABI Prism 7000 Sequence Detection System (Applied 
Biosystems) and the comparative threshold cycle (CT) method was used to 
determine mRNA concentration relative to 18S. 
  Immunohistochemistry.  Pieces of ovary from normal hens (n=5) and 
from hens with ovarian cancer (n=5) were fixed in 10% buffered formalin, 
embedded in paraffin and sectioned at 4-5 µm by the Cornell University 
Veterinary School.  Antigen was retrieved by incubation at 37°C with pronase. 
Sections were blocked with 10% goat serum in PBS for 30 min at 37°C and 
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treated with polyclonal rabbit anti-human VEGF antibody (Santa Cruz, 
diluted 1:25).  Control slides were treated with normal rabbit IgG (Upstate Self 
Signaling Solutions).  Secondary antibody was Alexa Fluor 488 goat anti- 
rabbit IgG conjugate (Molecular Probes, diluted to 1.3 µg/ml).  Sections were 
treated with secondary antibody for 1 h at 37°C.  To identify nuclei, sections 
were incubated with propidium iodide (Sigma, diluted to 1µg/ml) in PBS for 
15 min at room temperature following secondary antibody.  Hematoxylin and 
eosin staining was performed by the Cornell University Veterinary School. 
Slides were viewed using a Nikon eclipse E600 microscope and pictures were 
taken using a SPOT RT Slider camera. 
  Western Blot Analysis.  Ascites cell homogenates (n=4) and media 
collected from cell cultures (n=5 preparations) were concentrated using 
Microcon 30 devices (Millipore).  Protein concentrations were determined 
using a BCA Protein Assay Kit (Pierce) and 30g of total protein were loaded 
onto 10% Precise Protein Gels (Pierce) along with a Biotinylated protein ladder 
(Cell Signaling).  Electrophoresis was performed under reducing conditions 
and gels were blotted to nitrocellulose membranes (Thermo Scientific).  Blots 
were blocked in 1X Tris-buffered saline with 0.1% Tween-20 (TBST) containing 
5% milk for 30 min, washed and incubated overnight at 4°C with VEGF 
antibody (diluted 1:70) in TBST containing 1% milk.  Blots were washed and 
incubated with a peroxidase labeled goat anti-rabbit IgG (KPL, diluted 1:1000) 
and an anti-biotin antibody (Cell Signaling, diluted 1:1000) in TBST containing 
5% milk for 1 hour at room temperature.  Detection was performed using a 
Lumiglo Chemiluminescent Substrate Kit (KPL).  Western blot was performed 
with untreated cell homogenates and media at the lowest, medium, and 
highest dose of each NSAID tested in proliferation assays.   
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Immunocytochemistry.  Ascites cells (n=6 preparations) were fixed using 
methanol or 80% acetone. Cells were incubated with VEGF antibody (diluted 
1:10), COX-1 antibody ([16], diluted 1:10), COX-2 antibody ([16], diluted 1:25), 
or rabbit IgG at equivalent concentrations, followed by secondary antibody.   
  Treatments.  Aspirin (Sigma), SC-560 (Cayman Chemical), and NS-398 
(Cayman Chemical) were solubilized in dimethyl sulfoxide (DMSO, Sigma).  
Cells incubated in medium without treatment were included as controls.  For 
vehicle controls, cells were treated with the maximum concentration of DMSO 
used.   
  Prostaglandin Analysis.  Concentrations of PGE2 (pg/ml) were 
determined in media using a PGE2 EIA Kit (Cayman Chemical). 
  Cell Proliferation Analysis.  Number of viable cells was determined using 
the CellTiter 96 Aqueous One Solution Assay (Promega).  
  Statistics.  Data were analyzed using PROC GLM of SAS and means 
were compared using Duncan’s multiple range test. 
              Contribution of Authors.  ME Urick developed and completed the 
experiments presented in the manuscript.  Drs. JR Giles and PA Johnson 
contributed technical assistance, intellectual insight, and funding. 
 
Results 
VEGF mRNA expression is higher (p< 0.02) in cells isolated from 
ascites (n=6) as compared to normal ovarian samples (n=7, Fig. 3-1). VEGF 
mRNA expression is intermediate in samples collected from hens with ovarian 
tumors (n=7).  There is a trend for a correlation between VEGF mRNA  
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Letters indicate significant differences (p<0.02).  Bars indicate standard error 
(n=6-7). 
 
 
 
Figure 3-1.  VEGF mRNA expression in normal ovaries, ovarian tumors, and 
ascites from hens with ovarian cancer.   
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 expression in ascites cells and ascites volume (Fig. 3-2, p=0.087).    
Cytoplasmic VEGF is present in both normal ovaries (n=5) and ovaries 
of hens with ovarian cancer (n=5, Fig. 3-3).  Concentrated expression is 
observed in theca cells of normal ovaries (panel C arrow) and in glandular  
areas and the stroma surrounding glandular areas of ovarian tumors (panel D 
arrowheads).  IgG controls show no specific staining (panels G, H, I, & J).  
VEGF protein in ascites cells (n= 6 preparations) was detected by Western blot 
and immunocytochemistry (Fig. 3-4).  The VEGF band was observed at the 
expected size, approximately 24kDa (panel A).  Two cell phenotypes were 
observed within the primary cultures: round epithelial-like cells and cells that 
appeared dendritic or fibroblast-like.  VEGF protein (panel B) is localized to 
the cytoplasm of some epithelial and dendritic-like cells.  No staining is  
evident in IgG controls (panel C).  COX-1 and COX-2 mRNA and protein are 
expressed in ascites cells from tumor-bearing hens (Fig. 3-5).  No staining is 
evident in IgG controls (data not shown).   
PGE2 concentrations (pg/ml) were decreased in medium after 
treatment of cultures for two days with a nonspecific (aspirin), COX-1 specific 
(SC-560), or COX-2 specific (NS-398) NSAID (Fig. 3-6, n=2-3 preparations per 
dose of each treatment, p<0.05).  Proliferation assay results show a significant 
decrease in proliferation (p< 0.05) in cells treated with 200 and 300µm of SC-
560 (COX-1 inhibitor) but not in cells treated with equivalent doses of NS-398 
(COX-2 inhibitor) (Fig. 3-7, n=3-7 preparations per dose of each treatment).  
Proliferation was also decreased in cells treated with 5 and 10mM doses of 
aspirin (p< 0.05).   
VEGF mRNA in untreated ascites cells and cells treated with aspirin, 
SC-560, or NS-398 showed no decrease with any NSAID treatment (data not 
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    There is a trend for a significant correlation between VEGF expression in    
    ascites cells and ascites volume (p= 0.087). 
Figure 3-2.  VEGF mRNA expression in ascites cells graphed against the 
volume of ascites (ml).   
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Representative photomicrographs of normal ovary and ovarian tumor stained 
with hematoxylin and eosin (A, arrow indicates theca layer; B, arrowheads 
indicate glandular areas), VEGF antibody (C, arrow indicates theca staining; 
D, arrowheads indicate glandular and stromal staining), VEGF antibody and 
propidium iodide (PI; E, F), rabbit IgG (G, H), and rabbit IgG with PI (I, J).  
Scale bars represent 100 µm. 
 
 
 
 
 
Figure 3-3.  (Following Page)  VEGF immunohistochemistry results.   
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VEGF protein in two representative ascites cell homogenates (lanes 2 and 3) 
detected by Western blot (A; ladder lane 1).  Representative photomicrograph 
of ascites cells stained with VEGF antibody (B), and normal rabbit IgG (C).  
Scale bar represents 100 µm.   
 
 
 
Figure 3-4.  VEGF protein expression in ascites cells. 
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COX-1 (A) and COX-2 (C) mRNA, and COX-1 (B) and COX-2 (D) protein in 
cells isolated from ascites of hens with ovarian cancer.  Bars indicate standard 
error (n=6).  Scale bars represent 100 µm. 
Figure 3-5.  COX expression in ascites cells.  
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Prostaglandin E2 in media collected from ascites cells cultured for 2 days with 
a nonspecific (aspirin; doses = 5 µm - 10 mM), COX-1 specific (SC-560; doses = 
5 µm - 20 µm), or COX-2 specific (NS-398; doses = 5 µm - 20 µm) NSAID.  
Asterisks indicate significant decreases in PGE2 (p < 0.05).  Bars indicate 
standard error (n = 2-3). 
 
Figure 3-6.  Effects of NSAIDs on PGE2 production in ascites cells. 
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Proliferation of ascites cells treated for 4 days with DMSO (vehicle) or a 
nonspecific (aspirin), COX-1 specific (SC-560), or COX-2 specific (NS-398) 
NSAID.  Asterisks indicate significant decreases in proliferation (p < 0.05).  
Bars indicate standard error (n=3-7). 
Figure 3-7.  Effect of NSAIDs on ascites cell proliferation.   
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shown).  Similarly, no effect of any NSAID was found on VEGF protein (data 
not shown). 
Discussion 
To assess whether VEGF may be associated with ovarian cancer in the 
hen, we determined VEGF expression in ovarian tumors and ascites cells.  
Ovaries with tumors are often heterogeneous, with normal tissue intermixed 
with cancerous areas.  This might explain why we observed an intermediate  
amount of VEGF mRNA in ovarian tumor samples.  We found a trend for a 
correlation between VEGF mRNA expression of ascites cells and volume of 
ascites.  Data indicate that ascitic VEGF expression may be a useful prognostic 
factor for ovarian cancer patients [17] and our results suggest the same could 
be true for the hen.  
VEGF protein is evident in glandular regions and stroma surrounding 
glandular regions within ovarian tumors (Fig. 3-3 D&F).  We have previously 
shown localization of COX-1 protein to glandular areas of tumor sections [16].  
Expression of COX-1 and VEGF protein in glandular areas of ovarian tumors 
is similar to the findings of Gupta et al., which show that COX-1 mRNA 
expression is associated with VEGF mRNA expression in human ovarian 
cancer [14].  For this reason, we investigated the effects of a nonspecific, COX-
1 specific, and COX-2 specific NSAID on the proliferation of, and VEGF 
expression in, ascites cells.      
Aspirin, which is a more potent inhibitor of COX-1 than COX-2 [18], 
and the COX-1 specific inhibitor, SC-560, decreased the proliferation of ascites 
cells, whereas the COX-2 inhibitor did not.  These results are consistent with 
results from a mouse model of ovarian cancer which showed that SC-560 
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reduced the growth of tumors while a COX-2 selective inhibitor did not [19].  
Additionally, our previous report shows an increase in COX-1, but not COX-2, 
mRNA in ovarian tumors of the hen [16] and others have reported that COX-1 
is increased in human ovarian cancer rather than COX-2 [14, 20].  Avian 
clearance of NSAIDs was shown to be more rapid than human clearance and 
metabolic products of NSAIDs in birds have been shown to differ from 
humans [21-23]. These differences explain why higher doses of NSAIDs have 
been used in previous studies with avian tissue [24, 25] and were used in these 
experiments with chicken cells.  
PGE2 has been associated with ovarian cancer [16] and all three 
NSAIDs used in this study significantly reduced PGE2 levels at concentrations 
that did not affect proliferation. It was shown that the antiproliferative effects 
of NSAIDs may not be explained solely by decreased prostaglandin synthesis 
[26] and other known mechanisms of action of NSAIDs may explain their 
antiproliferative effects [reviewed in [27]].   
A COX-1 specific NSAID inhibited VEGF production by the OVCAR-3 
ovarian cancer cell line in a previous study, while a COX-2 specific NSAID did 
not [14].  The OVCAR-3 cell line is a human ovarian cancer cell line derived 
from peritoneal ascites of ovarian cancer patients.  Difference in results 
obtained from the OVCAR-3 cell line and our data may be due to species 
differences or the fact that OVCAR-3 cells are from a homogenous cell line, 
while our experiments used primary cultures.  We chose to utilize primary 
cultures to ensure that our results were as close to in vivo conditions as 
possible.  In vivo, interactions of malignant cells with other cell types may 
affect the viability of the malignant cells [28, 29] and may help explain why 
chemotherapeutic drugs do not have the same effects in vivo as in isolated 
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tumor cells [29].  Our results indicate that in vivo, treatments with NSAIDs 
may not affect VEGF production by cells found within ascites fluid.   
 This study is the first to report VEGF mRNA and protein expression in 
ovaries and ascites cells of tumor-bearing hens as well as normal hen ovaries.  
These data suggest that VEGF may play a role in ovarian cancer progression 
in the hen, including the accumulation of ascites.  Since ascites accumulation is 
inversely associated with survival (reviewed in 2), the hen might be a model 
to study therapies that target VEGF expression.  We have shown that the 
proliferation of ascites cells can be decreased using aspirin or a COX-1 specific, 
but not COX-2 specific, NSAID.  Our findings in the hen may or may not 
apply to epidemiological data that implicate NSAIDs as preventative agents in 
ovarian cancer initiation.  
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CHAPTER 4  
DIETARY ASPIRIN DECREASES THE STAGE OF OVARIAN CANCER IN 
THE HEN*  
Abstract 
Objective.  We aimed to determine the effects of dietary aspirin 
treatment on ovarian cancer incidence and progression in the hen as a model 
for the human disease. 
 Methods.  Hens were fed a standard layer diet (control) or the same diet 
containing 0.1% aspirin for 1 year.  Liver prostaglandin E2 (PGE2) was 
measured using an enzyme immunoassay.  Incidence and stage of ovarian 
cancer were determined through necropsy and immunohistochemical analysis 
of ovarian sections for each hen. 
 Results.  Aspirin treatment decreased liver PGE2 in treated hens as 
compared to control hens.  Treatment with aspirin did not decrease ovarian 
cancer incidence.  Significantly more control hens developed late stage ovarian 
cancer than early stage, while the same was not true for aspirin-treated hens.  
Hens that developed ovarian cancer, even early ovarian cancer, produced 
significantly fewer eggs in the year prior to diagnosis than hens without 
ovarian cancer. 
 Conclusions.  Aspirin treatment may inhibit the progression of ovarian 
cancer in the hen and egg production may be used to identify hens with early 
stages of the disease.         
 
                                                 
* This manuscript was submitted for consideration for publication in 
Gynecologic Oncology,  July 2008 
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Introduction 
Evidence suggests that frequent use of nonsteroidal anti-inflammatory 
drugs (NSAIDs) may aid in the prevention of carcinogenesis in tissues 
including the colon, breast, and pancreas [1-4].  In addition, epidemiological 
studies indicate that the use of aspirin or other NSAIDs may be associated 
with a risk reduction for ovarian cancer [5-8].  Several observational studies, 
however, demonstrate no association between ovarian cancer risk and NSAID 
use [reviewed in 9].  Wernli et al. recently hypothesized that the contradictions 
in results may be due to differences in factors such as parity and oral 
contraceptive use across study populations.  They found a reduction in 
ovarian cancer risk associated with the use of NSAIDs in women who never 
used oral contraceptives or were nulliparous.  They did not find a risk 
reduction in women who used oral contraceptives or parous women, possibly 
because these groups of women already had reduced risks of ovarian cancer 
[9].  The inconsistency of results in epidemiological studies illuminates the 
need for laboratory and clinical studies to test the efficacy of NSAIDs to 
decrease ovarian cancer risk and/or progression. 
The ability of NSAIDs to negatively affect the viability of ovarian 
cancer cells in vitro has been shown by a number of studies [10-14].  Results 
using nude mice xenografted with tumors derived from human ovarian 
cancer cell lines show that NSAIDs have anti-proliferative effects in vivo [13, 
15].  No study to date, however, has investigated the effect of NSAIDs in a 
spontaneous in vivo model of ovarian cancer.  The hen is the only animal that 
spontaneously develops ovarian cancer at a rate high enough to study [16, 17].  
We have previously shown that aspirin (a common nonspecific NSAID) or a 
COX-1 specific NSAID can decrease the viability of ascitic cells collected from 
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hens with ovarian cancer [18].  The purpose of the following experiment was 
to examine the effects of dietary aspirin treatment on ovarian cancer incidence 
and progression in the hen as a model for the human disease. 
 
Materials and Methods 
Experimental Design.  Three age groups (Table 4-1) of the Babcock B300 
strain of single-comb White Leghorn hens were individually caged, with free 
access to water and feed.  Hens were maintained on a 15 hour light and 9 hour 
dark schedule.  Half of the hens in each group were fed a standard layer diet 
(control, n=99), while the other half were fed the same diet which contained 
0.1% aspirin (aspirin-treated, n=99) for 1 year.  Eggs were collected daily and 
birds were weighed monthly.  Percent egg production was calculated by 
dividing the number of days an egg was produced by the total number of 
days per month.  Necropsy was performed on all hens, including those that 
died prior to the end of the experiment (n=30 control; n=28 aspirin-treated), as 
well as hens euthanized (CO2) at the end of the experiment (n=69 control; 
n=71 aspirin-treated).  Animal procedures were approved by the Institutional 
Animal Care and Use Committee of Cornell University.     
 Sample Collection.  Samples of ovary from all hens were fixed in buffered 
formalin for immunohistochemical analysis.  Samples of liver were collected 
from hens euthanized at the end of the experiment and snap frozen in liquid 
nitrogen for prostaglandin analysis. 
PGE2 Immunoassay. PGE2 was extracted from liver samples according to 
the manufacturer’s protocol (Cayman Chemical) and measured using a PGE2  
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Table 4-1.  Three age groups used for the in vivo study.   
Ending age shows the age of the hens in each group that survived until the 
end of the experiment (n=57 from the 2006 hatch, 47 from the 2005 hatch, 36 
from the 2004 hatch). 
 
 
Starting Age 
(years) 
Ending Age 
(years) 
Starting Number of 
Hens 
2006 
Hatch 
0.5 1.5 60 
2005 
Hatch 
1.5 2.5 60 
2004 
Hatch 
2.5 3.5 78 
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EIA Kit (#514010).  Concentrations (pg/mL) were estimated from absorbance 
compared to the standard curve using the data analysis tool provided by 
Cayman Chemical and normalized to the weight of the liver sample (g) used 
for extraction.    
 Immunohistochemical Analysis.  Paraffin sections were cut and 
hematoxylin and eosin staining of ovarian sections was performed by the 
Cornell Histology Laboratory.  Two investigators blinded to the experimental 
treatment analyzed at least two sections from each hen.  Sections were 
identified as containing cancerous cells (cancer) or no significant neoplastic 
lesions (NSL).  Diagnosis of cancer was based on the classifications in Table 4-
2, which were adapted from previous staging systems used in hens [17, 19].   
 Statistics.  Data were analyzed using SAS.  PGE2 and egg production 
data were analyzed using the PROC GLM function and means were compared 
using Duncan’s multiple range test.  Overall cancer incidence was analyzed 
using the PROC LOGISTIC function.  Analyses of cancer incidence with 
respect to age and tumor stage data were performed using the PROC FREQ 
function followed by a chi-square test of independence.  Survival data were 
analyzed using the PROC LIFETEST function.  Completion of a power 
analysis to establish initial sample size and determination of relevant 
statistical analyses were made after consultation with a statistician at the 
Cornell Statistical Counseling Unit.   
 
Results 
When hens with ovarian cancer or other pathology noted at necropsy 
were excluded, aspirin caused a significant decrease in PGE2 in treated hens as 
compared to control hens (p<0.05, Fig. 4-1).  The incidence of ovarian cancer  
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Table 4-2.  Stages of ovarian cancer in the hen.  
       Adapted from previous staging systems used in the hen [17, 19]. 
 
Stage Description 
1 Tumor restricted to ovary and detectable by histology 
2 Tumor restricted to ovary and observable at necropsy 
3 Extensive ovarian tumor with abdominal seeding 
4 Extensive ovarian tumor with abdominal seeding and ascites  
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Prostaglandin E2 (PGE2) in liver samples collected from a random subset of 
hens that lacked noticeable pathology at necropsy and were fed standard layer 
diet (Control, n=11) or standard layer diet containing 0.1% aspirin (Aspirin, 
n=12) for 1 year.  The asterisk indicates a significant decrease in PGE2 (p<0.05).  
Bars indicate SEM. 
 
 
Figure 4-1.  Effect of dietary aspirin on liver PGE2 production.  
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significantly increased with age in both control and aspirin treated hens 
(p<0.05, Fig. 4-2).  Treatment of hens for 1 year with 0.1% aspirin did not  
significantly decrease ovarian cancer incidence when all three age groups 
were analyzed together (Table 4-3, All Hens).  We found, however, that there 
were significantly more control hens with late stage ovarian cancer (stages 3 or 
4) than early stage ovarian cancer (stage 1 or 2), while the same was not true 
for aspirin-treated hens (p<0.05, Table 4-4).  Additionally, aspirin treatment 
may increase the survival of hens with ovarian cancer as compared to control 
hens (Fig. 4-3, p=0.26). Data from the 2005 hatch hens also show the potential 
for aspirin to decrease ovarian cancer incidence (Table 4-3, 2005 Hatch).  
No differences in egg production (Fig. 4-4) or body weight (data not 
shown) were observed in aspirin-treated hens as compared to control hens.  In 
addition, no obvious gastric or intestinal pathologies were noticeable at 
necropsy, but thorough examination of tissues was not performed.  We found 
a significant decrease in egg production in hens that developed ovarian cancer 
as compared to hens without ovarian cancer (p<0.05, Fig. 4-4).   Additionally, 
we found that hens with stage 1 ovarian cancer have significantly decreased 
egg production in the year preceding diagnosis as compared to hens that do 
not have ovarian cancer (p<0.05, Fig. 4-5).    
 
Discussion 
The dose of 0.1% aspirin in feed was chosen based on results from a 
pilot study, which showed decreased COX activity in liver samples of hens fed 
this dose of aspirin.  Moreover, previous work in the hen showed that 0.1% 
dietary aspirin decreased the production of shell-less eggs through the 
inhibition of prostaglandins in the reproductive tract [20], while increased  
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A significant increase in ovarian cancer incidence with age was 
found (p<0.05; control and aspirin-treated combined). 
 
 
Figure 4-2.  Percent of hens with ovarian cancer. 
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Table 4-3.  Percent ovarian cancer in control and aspirin-treated hens. 
Results for all hens at the end of the experiment. 
 
 2006 Hatch 2005 Hatch 2004 Hatch All Hens 
Control 0.0 (0/30) 23.3 (7/30) 51.3 (20/39) 27.3 (27/99) 
Aspirin 3.3 (1/30) 16.7 (5/30) 59.0 (23/39) 29.3 (29/99) 
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Table 4-4.  Stage of ovarian cancer in control and aspirin-treated hens.  
Number of hens (3 age groups combined) with early stage (stages 1 and 2) and 
late stage (stages 3 and 4) ovarian cancer in hens fed standard layer diet 
(Control) and hens fed standard layer diet containing 0.1% aspirin (Aspirin).  
There is a significantly higher incidence of late stage ovarian cancer than early 
stage ovarian cancer in the control hens (p<0.05). 
 
 Early Stage Late Stage % Late Stage 
Control 4 23 85.2* 
Aspirin 11 18 62.1 
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Although not significant (p=0.26), aspirin-treated hens with ovarian cancer 
(Aspirin Cancer) survived longer than control hens with ovarian cancer 
(Control Cancer). 
Figure 4-3.  Percent survival for each month of the experiment.   
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Percent egg production in hens fed control diet that developed ovarian cancer 
(Control Cancer, n=27), hens fed control diet that did not develop ovarian 
cancer (Control NSL, n=71), hens treated with aspirin that developed ovarian 
cancer (Aspirin Cancer, n=29), and hens treated with aspirin that did not 
develop ovarian cancer (Aspirin NSL, n=69).  Hens that developed ovarian 
cancer produced significantly fewer eggs than hens without ovarian cancer 
(p<0.05).  Bars indicate SEM. 
 
 
 
Figure 4-4.  Egg production in control and aspirin-treated hens with 
ovarian cancer.   
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Percent egg production in hens fed control diet that did not develop ovarian 
cancer (Control NSL, n=71), hens treated with aspirin that did not develop 
ovarian cancer (Aspirin NSL, n=69), and hens with stage 1 ovarian cancer 
(Stage 1, n=12; 3 control hens, 9 aspirin-treated hens).  Hens with stage 1 
ovarian cancer produced significantly fewer eggs than hens without ovarian 
cancer (p<0.05).  Bars indicate SEM. 
Figure 4-5.  Egg production in hens with stage 1 ovarian cancer.  
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Mortality was observed with a higher dose (0.2%) of aspirin [21].  In order to 
verify that 0.1% aspirin was a sufficient dose to affect systemic COX activity, 
we measured PGE2 levels in liver samples from control and aspirin-treated 
hens.  We previously found increased PGE2 in ovarian tumors of the hen as 
compared to normal ovaries [22] and PGE2 is elevated in human ovarian 
cancer [23, 24].  We therefore chose to evaluate liver PGE2 as a measure of the 
systemic effects of aspirin treatment.  There was an overall trend for a 
decrease in PGE2 in the liver of aspirin-treated hens as compared to control 
hens (p=0.0897) but the various pathologies associated with the failing health 
of the 2004 hatch hens, including ovarian cancer, may have affected liver PGE2 
levels.  When the hens with failing health were removed, there was a 
significant decrease in PGE2 levels in the liver of aspirin-treated hens as 
compared to control hens (p<0.05, Fig. 4-1).  
 Fredrickson showed an increase in ovarian cancer incidence in White 
Leghorn hens after 2 years of age [17].  The incidence of ovarian cancer in the 
Babcock B300 commercial strain of White Leghorn hens had not been 
characterized prior to this study and, therefore, three different ages of hens 
were used (Table 4-1).   Our findings verify the increase in ovarian cancer 
incidence in hens after 2 years of age (p<0.05, Fig. 4-2), and additionally show 
a higher incidence (55.1% at 3.5 years of age) in Babcock B300 hens than has 
been previously reported for other strains [17, 25-27].  These data indicate that 
this modern commercial strain may be particularly useful for ovarian cancer 
studies in the hen.     
Although we did not find a significant effect on cancer incidence, we 
observed a significant decrease in the stage of ovarian cancer in aspirin-treated 
hens as compared to control hens (p<0.05, Table 4-4).  This could indicate that 
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aspirin treatment may have decreased the progression of ovarian cancer.  
Aspirin also tended to increase the survival of hens with ovarian cancer (Fig. 
4-3).   
Only one hen in the 2006 hatch hens was identified with ovarian cancer 
and therefore, it might have been advantageous to treat these hens for longer 
than 1 year.  This may have permitted a determination of the efficacy of 
aspirin to prevent the initiation of ovarian tumors.  The 2004 hatch hens were 
2.5 years old at the start of the experiment and showed a high incidence 
(85.0% of control; 69.6% of aspirin-treated) of late stage ovarian cancer.  This 
suggests that ovarian carcinogenesis had initiated in many of these hens prior 
to the onset of the experiment.  The decrease in the percentage of late stage 
ovarian cancer in aspirin-treated hens of this hatch suggests that aspirin 
treatment may decrease the progression of ovarian cancer even if treatment 
begins after carcinogenesis is initiated.  
Based on previous data documenting an increase in ovarian cancer 
incidence in hens after 2 years of age [17] and the fact that only one hen was 
identified with ovarian cancer in the 2006 hatch hens (ending age of 1.5 years), 
it is likely that most of the hens in the 2005 hatch (starting age 1.5 years) did 
not have ovarian cancer at the onset of this experiment.  In addition, at the end 
of the experiment, these hens were 2.5 years of age (Table 4-1).  The data from 
these hens, therefore, may provide the most insightful information regarding 
the effect of aspirin intake on ovarian cancer incidence.  We found a 
significant decrease in stage of ovarian cancer with aspirin treatment in hens 
of this age (p<0.05; 2005 Hatch data not shown separately) and a potential for 
aspirin to decrease ovarian cancer incidence (Table 4-3, 2005 Hatch).  
Additionally, 50% (3/6) of 2005 Hatch control hens that died prior to the end 
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of the experiment were diagnosed with ovarian cancer, while only 14.3% (1/7) 
of aspirin-treated hens of this age died with ovarian cancer.  A more 
pronounced effect of aspirin treatment on ovarian cancer incidence and/or the 
survivability of hens with ovarian cancer may have been observed if the hens 
were allowed to survive until natural death. 
There was a significant decrease in egg production in hens with ovarian 
cancer (p<0.05, Fig. 4-4). This may suggest that egg production can be used to 
identify hens with the disease.  Sonography is currently the only method of 
detection in the hen that does not require euthanasia of the animal [19] and 
monitoring egg production may be a more convenient method to distinguish 
hens with ovarian cancer.  The failing health of hens with advanced stages of 
ovarian cancer may arguably have caused the decrease in egg production 
shown in Figure 4-4.  Our data show, however, that hens with stage 1 ovarian 
cancer produce significantly fewer eggs in the year prior to diagnosis than 
hens that do not have ovarian cancer (p<0.05, Fig. 4-5).  Stage 1 ovarian cancer 
in the hen can only be detected histologically (Table 4-2), which suggests that 
egg production decreases before the disease has significantly affected the 
overall health of the hen.  A decrease in egg production may therefore identify 
hens with an earlier stage than can be identified with physical inspection or 
sonography.  Studies in our laboratory are currently underway to confirm and 
assess this method.     
To our knowledge, this is the first study to evaluate the effectiveness of 
aspirin in decreasing ovarian cancer incidence in the hen.  The fact that the 
hen spontaneously develops ovarian cancer permits the in vivo testing of 
chemotherapeutic or chemopreventative agents.  This study provides vital 
information and encouraging data for future studies evaluating these agents 
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using hens.  Dietary aspirin decreased liver prostaglandin production and 
resulted in a significantly reduced stage of ovarian cancer.  This suggests that 
aspirin may inhibit the progression of the disease.  Our data also indicate that 
a decrease in egg production may be used to distinguish hens with early 
stages of ovarian cancer.  Finally, we have identified a commercial strain of 
White Leghorn hens as having a higher incidence of ovarian cancer at 3.5 
years than previously noted. 
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CHAPTER 5  
SUMMARY AND INTERPRETATION OF RESULTS 
 Our data indicate that COX-1 mRNA is significantly increased in 
ovarian tumors of the hen as compared to normal hen ovaries, while there is 
no difference in COX-2 mRNA between normal ovaries and ovarian tumors 
(chapter 2).  Prostaglandin E2 (PGE2) levels were also significantly increased in 
ovarian tumors as compared to normal ovaries, which indicates that the 
increase in COX-1 mRNA was a functional increase.  In addition, COX-1 
protein localized to glandular areas of ovarian tumors.  These data are similar 
to findings in women, which indicate that ovarian cancer exhibits increased 
expression of COX-1 rather than COX-2 [1-3].  Expression data from women 
and our data from the hen, therefore, both suggest that COX-1 is more highly 
correlated with ovarian adenocarcinoma than COX-2. 
 The accumulation of large volumes of malignant ascites is often 
associated with advanced stages of ovarian cancer in women [reviewed in [4]], 
as well as in the hen.  In order to further elucidate the roles of both COX 
enzymes in ovarian cancer progression, we determined the expression of both 
isoforms in ascites cells collected from hens with ovarian cancer and studied 
the effects of treatment of the cells with different nonsteroidal anti-
inflammatory drugs (NSAIDs) (chapter 3).  We found mRNA and protein 
expression of both COX isoforms in cells isolated from ascites collected from 
hens with ovarian cancer.  Treatment with aspirin (a nonspecific NSAID that 
is a more potent inhibitor of COX-1 than COX-2 [5]) or SC-560 (a COX-1 
specific NSAID) significantly decreased the proliferation of ascites cells, while 
equivalent concentrations of NS-398 (a COX-2 specific NSAID) did not 
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significantly affect proliferation.  These results support data from a mouse 
model of ovarian cancer, which showed that SC-560 reduced the growth of 
tumors while a COX-2 selective inhibitor did not [1].  These data in 
combination with our characterization data further suggest that COX-1 may 
play a more prominent role in ovarian carcinogenesis than COX-2.   
Vascular endothelial growth factor (VEGF) expression has been 
positively correlated to the metastasis of ovarian cancer cells as well as to 
peritoneal ascites accumulation in women [6].  Interestingly, VEGF expression 
has also been correlated to COX-1 expression in ovarian cancer in women.  
Colocalization of COX-1 and VEGF mRNA were reported and a COX-1 
specific NSAID inhibited VEGF production by an ovarian cancer cell line, 
while a COX-2 selective inhibitor did not [3].  Therefore, we wanted to 
determine whether treatment with NSAIDs affected the expression of VEGF in 
ascites cells collected from hens with ovarian cancer (chapter 3).  We found 
VEGF mRNA and protein expression in ascites collected from hens with 
ovarian cancer as well as in ovarian tumors.  Although we did not observe a 
decrease in VEGF expression with any NSAID treatment, we did find that 
VEGF mRNA expression was significantly increased in ascites cells as 
compared to normal hen ovaries.  Additionally, we found a positive 
correlation between VEGF mRNA expression in ascites cells and ascites 
volume.  These data suggest that VEGF may be a useful prognostic factor for 
ovarian cancer in the hen, as it also may be in women [7].   
The agreement between the results from our first two studies (chapters 
2 & 3) and those found in studies with ovarian cancer patients provide strong 
evidence that the hen is a valid model to use in studies testing the efficacy of 
treatments targeting the COX enzymes.  Epidemiological studies indicate that 
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the use of aspirin or other NSAIDs may be associated with a risk reduction for 
ovarian cancer [8-11].  At least five observational studies, however, 
demonstrate no association between ovarian cancer risk and NSAID use 
[reviewed in [12]].  No clinical trials have been reported examining the 
effectiveness of NSAID treatments in decreasing ovarian cancer risk, 
decreasing the progression of the disease, or enhancing the efficacy of current 
treatments.  The purpose of the final study presented in this dissertation 
(chapter 4), therefore, was to complete the first in vivo study examining the 
effects of aspirin on ovarian cancer incidence and progression in the hen, the 
only animal that spontaneously develops the disease at a rate high enough to 
study.  
Although we did not find a significant effect on cancer incidence, we 
did observe a significant effect of aspirin treatment on the stage of ovarian 
cancer, which indicates that aspirin may slow the progression of the disease.  
Our data also indicate that treatment with aspirin may potentially decrease 
ovarian cancer incidence or increase the survivability of hens with ovarian 
cancer as compared to untreated hens if the hens are allowed to survive until 
natural death.  This experiment not only provided vital information and 
encouraging data for future studies using the hen for in vivo studies, it also 
added to the growing amount of evidence suggesting that NSAIDs may be 
useful as chemotherapeutic or chemopreventative agents for ovarian cancer 
[8-12].   
In addition to providing novel data regarding the potential role of the 
COX enzymes in ovarian carcinogenesis, the experiments presented in this 
dissertation provided additional information regarding the hen model.  We 
identified the commercial Babcock B300 strain of single-comb White Leghorn 
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hens as having a higher incidence of ovarian cancer than has been previously 
reported for other strains [13-16] and have verified the age-dependency of 
ovarian cancer incidence that was observed by Fredrickson in 1987 [13] 
(chapter 4).  In addition, we found that hens with ovarian cancer produce 
significantly fewer eggs in the year prior to diagnosis (chapter 4).  This finding 
is in contrast to data reported by Fredrickson [13], which showed no 
difference in egg lay between hens that developed genital tumors and those 
that did not.  Continuous laying records were not maintained for individual 
birds in Fredrickson’s study, however.  The number of eggs for individual 
hens was recorded by trapping hens as they entered nests for 14 
nonconsecutive months over the 3.5-year observational period [13].  The hens 
in our experiment were individually caged, which permitted the recording of 
continuous laying records for each hen and may explain the difference in 
results.  According to our results, monitoring egg production may provide a 
new method to detect ovarian cancer in the hen.   
Sonography and palpation are the only current methods of detection 
that do not require anesthesia [17].  Our data show that hens with stage 1 
ovarian cancer, which can only be detected histologically, lay significantly 
fewer eggs in the year prior to diagnosis than hens that do not have ovarian 
cancer (chapter 4). This indicates that monitoring egg production may be a 
more sensitive method of detection than sonography.  The mechanism behind 
the decrease in egg lay in hens with stage 1 ovarian cancer is unknown.  
Examination of histological sections in our lab has led to the observation that 
early lesions in hen ovaries may frequently occur near postovulatory follicles 
(unpublished observation).  The hen postovulatory follicle (POF) serves as a 
source of prostaglandins that play a role in stimulating oviposition, which is 
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demonstrated by a delay in oviposition observed after removal of the POF [18, 
19].  It is possible that a neoplastic lesion near the POF may disrupt 
prostaglandin production and result in an initial delay in oviposition.  A 
subsequent decrease in egg lay may follow as the neoplasm affects the normal 
hormonal milieu of the ovary.  The ability of hen ovarian tumors to produce 
steroid hormones is indicated by the presence of 3-beta-hydroxysteroid 
dehydrogenase (3-β-HSD) in glandular areas of ovarian tumors, which 
suggests that these tumors can synthesize progesterone and androgens [20].  
Progesterone produced from the F1 follicle stimulates the release of GnRH 
from the hypothalamus, which in turn triggers the LH surge prior to ovulation 
in the hen.  Continuous production of progesterone from the ovarian tumor 
could therefore negatively feedback to the hypothalamic-pituitary axis and 
decrease gonadotropin production, which would ultimately inhibit ovulation.  
Progesterone produced by neoplastic cells could also inhibit ovulation 
through the disruption of follicular development.  Studies have shown that 
administration of large doses of progesterone causes follicular atresia and 
inhibition of ovulation [21].  Testosterone has also been shown to stimulate 
ovulation [22] and a testosterone antagonist was shown to inhibit ovulation 
and preovulatory surges of progesterone, LH, and estradiol in laying hens 
[23].  Production of testosterone by neoplastic cells, therefore, could also act 
through a negative feedback mechanism to disrupt ovulation.  Alternatively, 
the decrease in egg lay in hens with stage 1 ovarian cancer may reflect a prior 
hormonal imbalance that affected egg lay and facilitated the formation of the 
neoplasm.     
In summary, we have presented novel data showing the expression of 
the COX enzymes and VEGF in the normal hen ovary and over-expression of 
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COX-1 and VEGF mRNA in ovarian adenocarcinomas of the hen.  We have 
published the first work using ascites cells collected from hens with ovarian 
cancer and have shown that the proliferation of these cells can be decreased 
using aspirin or a COX-1 specific NSAID.  Finally, we have completed the first 
in vivo study testing the efficacy of NSAIDs in decreasing the risk or 
progression of ovarian cancer in the only spontaneous model of the disease 
and have shown a significant effect on the stage of ovarian cancer with aspirin 
treatment.  Taken together, the studies presented in this dissertation provide a 
significant contribution of literature that validates utilizing the hen as a model 
for ovarian cancer as well as provides experimental evidence that the COX 
enzymes are involved in ovarian carcinogenesis.     
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